Antimicrobial Compositions and Related Methods of Use

ABSTRACT

Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical, personal care and/or animal care products and applications.

This application claims priority benefit from U.S. application Ser. No.13/815,839 filed Mar. 15, 2013, which is incorporated herein byreference in its entirety.

BACKGROUND OF THE INVENTION

Much progress has been made toward identification and development ofbiocides for controlling various molds, plant diseases and the like.However, most commercial biocides or pesticides in use are compoundswhich are classified as carcinogens or are toxic to wildlife and othernon-target species. For example, methyl bromide is widely used as a soilfumigant and in the post-harvest treatment of microbial infections.Human toxicity and deleterious environmental effects will ultimatelyresult in discontinued use of methyl bromide and various other syntheticbiocides/pesticides. As a result, recent efforts have been directed tothe identification and development of natural or biomimetic compositionsdemonstrating comparable antimicrobial or pesticidal effect.

One such approach relates to endophytes and associated volatileby-products. Endophytes are defined in the art as microorganismsresiding in the interstitial spaces of living plant tissue, but aregenerally not considered to be parasitic. In particular, endophytesfound in conjunction with rain forest plants have generated considerableinterest for reasons relating to the antibiotic character of theirvolatile by-products. Several members of the Muscodor genus (i.e., M.albus, M. roseus and M. vitigenus) have been shown to produce volatileby-products exhibiting antibiotic or insecticidal character. However,the respective by-product of each species includes various naphthaleneand/or azulene derivatives. Such compounds, together with otherby-product components, can be toxic or otherwise unhealthy, and thecorresponding mixtures are considered unacceptable for various end useapplications. Accordingly, there remains an on-going search in the artto identify natural compositions and to develop biomimetic compositionsabsent from such compounds, that are safe for human use and demonstrateeffective antimicrobial properties.

SUMMARY OF THE INVENTION

In light of the foregoing, it is an object of the present invention toprovide flavorings that have antimicrobial compositions and/or methodsfor their use, thereby overcoming various deficiencies and shortcomingsof the prior art, including those outlined above. It will be understoodby those skilled in the art that one or more aspects of this inventioncan meet certain objectives, while one or more other aspects can meetcertain other objectives. Each objective may not apply equally, in allits respects, to every aspect of this invention. As such, the followingobjects can be viewed in the alternative with respect to any one aspectof this invention.

It can be an object of the present invention to provide a Muscodorspecies and a volatile by-product thereof, absent naphthalene andazulene (non-GRAS compounds) related compounds, in conjunction with amethodology for the prevention, inhibition and/or eradication ofmicrobial infection.

It can be another object of the present invention to provide a systemcomprising such a species or strain thereof and an associated volatileby-product in conjunction with a non-indigenous medium or substrate foruse against microbial infection.

It can be another object of the present invention to provide such asystem and/or related methodology for use, without limitation, in thecontext of human and animal food, produce, plants, plant parts, seeds,agricultural crops and other organic materials, packaging, buildingmaterials, fibers, cloth, clothing articles, and pharmaceutical and/ormedical applications.

It can be another object of the present invention to provide, in thealternative or in conjunction therewith, a range of biomimetic man-madecompositions demonstrating antimicrobial activity comparable to suchMuscodor species.

It can be an object of the present invention to provide one or more suchcompositions of components edible or otherwise safe for human use andconsumption.

It can be another object of the present invention to provide a system,composite or article comprising such a non-natural, biomimeticcomposition in conjunction with a medium or substrate for theprevention, inhibition and/or eradication of microbial infection. It canbe another object of the present invention to provide such a system,composite and/or article for use, in a context of the sort describedabove or illustrated elsewhere herein.

It can also be an object of the present invention to provide a methodfor antimicrobial and/or pesticidal treatment comprising such acomposition, without limitation as to medium, carrier or substrate.

Other objects, features, benefits and advantages of the presentinvention will be apparent from this summary and the followingdescriptions of certain embodiments, and will be readily apparent tothose skilled in the art having knowledge of various antimicrobialcompositions and related treatments. Such objects, features, benefitsand advantages will be apparent from the above as taken into conjunctionwith the accompanying examples, data, figures and all reasonableinferences to be drawn therefrom, alone or with consideration of thereferences incorporated herein.

In part, the present invention can be directed to a system comprising atleast one of a strain of M. crispans, a volatile by-product thereof orvapor of such a volatile by-product and a non-indigenous medium orsubstrate. Such media or substrates can be as described herein or aswould otherwise be understood by those skilled in the art. Regardless,such a strain can be provided in the form of a biologically pureculture, optionally in conjunction with a carrier component suitable formedia/substrate contact or end-use application, such a culturesufficiently viable for production of a volatile by-product. Inaccordance with this invention, a by-product or a modification of aby-product of M. crispans, or vapor corresponding thereto, is ascompositionally described elsewhere herein.

Accordingly, the present invention can also be directed to using such asystem and/or the volatile fungal by-products thereof to provideantimicrobial effect. Such a method can comprise providing anon-indigenous substrate or medium capable of supporting microbialactivity or growth; and contacting such a substrate or a medium with aculture of a strain of M. crispans, a volatile by-product thereof and/orvapor from such a by-product. In certain embodiments, such contact cancomprise such a strain on, about or approximate to such a medium orsubstrate. In certain other embodiments, a volatile by-product ormodifications of a by-product of M. crispans, or a corresponding vapor,can infuse or otherwise contact such a medium or substrate.

Without limitation as to any such system or method, such a substrate canbe selected from a food or produce item, a packaging component for afood or other perishable item, a fiber, clothing or clothing item, abuilding or construction component, a plant, plant surface, soil,garbage or refuse. Such contact can be bioactive with respect tomicrobial presence and/or prophylactic.

In part, the present invention can be directed to a non-naturallyoccurring antimicrobial composition, whether the components thereof arenaturally-derived, chemically-synthesized or a combination thereof. Sucha composition can comprise compounds selected from alcohol, aldehyde,ketone, acid and/or acid ester components of a biomimetic Muscodor sp.by-product composition, such a composition as can be absent fusedaromatic compounds, substituted fused aromatic compounds and hydroderivatives of such compounds. In certain non-limiting embodiments, sucha composition can comprise an acid component selected from acetic acid,isobutyric acid, propanoic acid and combinations thereof.

In certain embodiments, the present invention can be directed to anaturally-derived antimicrobial composition comprising a C₂-about C₅acid component; a C₂-about C₅ ester component; and at least two C₂-aboutC₅ components isolatable from a volatile by-product of an isolatedculture of Muscodor crispans, such a composition as can have a pathogenactivity profile different from a pathogen activity profile of anisolated, cultured Muscodor sp., a volatile by-product thereof and/or asynthetic mixture of such a volatile by-product. Such an acid componentcan be selected from isobutyric acid, propanoic acid and combinationsthereof. Independently, such an ester component can be selected from aC₄ ester acetate, a C₅ ester acetate and combinations thereof.

In certain other embodiments, such a composition can comprise propanoicacid, and a component selected from a C₂-about C₅ acid ester, analdehyde and combinations thereof. In certain such embodiments, an acidester component can be selected from acetic acid esters, isobutyric acidesters and combinations thereof. One such embodiment can consistessentially of propanoic acid and isobutyl isobutyrate. Another suchembodiment can consist essentially of propanoic acid, isoamyl acetateand an aldehyde such as benzaldehyde.

Without limitation, in certain other embodiments, such a composition cancomprise about 8-about 10 components otherwise isolatable from avolatile by-product of M. crispans. In certain such embodiments, eachcomponent of such a composition can be isolatable from such a volatileby-product. As such a composition can be naturally-derived, each suchcomponent can be a fermentation product, and fermentation can beselected from bacterial, yeast and/or fungal fermentations. Regardless,each such component of such a composition can be generally recognized assafe for human consumption under Chapter 21 of the United States Code ofFederal Regulations and corresponding sections and/or provisionsthereof.

Regardless, in certain non-limiting embodiments, such an isolatablecomponent can be isobutyric acid. In certain such embodiments, propanoicacid can be at least in part substituted for isobutyric acid. In such orother non-limiting embodiments, such an isolatable component can be2-butanone. In certain such embodiments, acetic acid, propanoic acid ora combination thereof can at least in part be substituted for2-butanone. In such or yet other non-limiting embodiments, such anisolatable component can be ethanol. In certain such embodiments, aceticacid can be at least in part substituted for ethanol. Regardless of theidentity or amount of any such acid component, ester component and/orisolatable component, such a naturally-derived composition can comprisea surfactant component. In certain such embodiments, a biosurfactant canbe incorporated therewith. Without limitation, a biosurfactant can be arhamnolipid component selected from a monorhamnolipid, a dirhamnolipidand combinations thereof.

Alternatively, the present invention can be directed to a synthetic,non-naturally derived antimicrobial composition. Such a composition cancomprise a C₂-about C₅ acid component; a C₂-about C₅ ester component;and at least two C₂-about C₅ components isolatable from a volatileby-product of an isolated culture of Muscodor crispans, such acomposition as can have a pathogen activity profile different from apathogen activity profile of an isolated, cultured Muscodor sp. or avolatile by-product thereof. Such acid, ester and/or isolatablecomponents can be as described above or illustrated elsewhere herein.Regardless, such an antimicrobial composition can comprise a surfactantcomponent. In certain such non-limiting embodiments, such a surfactantcan be a rhamnolipid component selected from a monorhamnolipid, adirhamnolipid and combinations thereof.

In part, the present invention can be directed to a biomimetic,antimicrobial composition comprising a liquid mixture of compoundsselected from C₂ to about C₅ alcohols, aldehydes, ketones, acids andacid esters and combinations and sub-combinations thereof, such acomposition not isolated from Muscodor sp. As discussed elsewhereherein, such a liquid mixture can be volatile at room and/or ambienttemperatures. With respect to such a composition and the compoundsthereof, the term “about” can mean, as would be understood by thoseskilled in the art, carbon and/or methylene homologs with correspondingmolecular weight and/or structural isomerism limited only by mixturewith one or more other components, compounds and at least partialroom/ambient temperature volatility of the resulting composition. Withrespect to certain non-limiting embodiments, such a composition cancomprise alcohol, aldehyde, ketone, acid and acid ester compoundsselected from components of a biomimetic M. crispans by-productcomposition, of the sort described below. Such a composition cancomprise compounds chemically synthesized, compounds isolated frombacterial fermentation and combinations of such compounds. In certainsuch embodiments, such a composition can comprise an acid componentselected from acetic acid, isobutyric acid, propanoic acid andcombinations thereof.

In part, the present invention can also be directed to anon-naturally-occurring, whether naturally-derived and/orchemically-synthesized, antimicrobial composition comprising compoundsselected from C₂ to about C₅ alcohols, aldehydes, ketones, acids andacid esters and combinations and sub-combinations of such compounds,such selected compounds generally recognized as safe (“GRAS”) for humanconsumption, such designation as provided in Chapter 21 of the UnitedStates Code of Federal Regulations and corresponding sections and/orprovisions thereof. In certain non-limiting embodiments, such compoundscan be selected from alcohol, ketone, acid and/or acid ester componentsof a biomimetic M. crispans by-product composition. In certainembodiments, a microbe activity/mortality profile thereof differs fromthat of either M. crispans or M albus, a volatile by-product thereofand/or corresponding synthetic by-product compositions thereof.Regardless, in certain such embodiments, such a composition can comprisean acid component selected from acetic acid, isobutyric acid, propanoicacid and combinations thereof.

In part, the present invention can comprise a composition comprising acomposition of this invention; and a surfactant component, such asurfactant component alone or as can be incorporated into a carriercomponent. In certain embodiments, such a surfactant can be abiosurfactant, such a biosurfactant as can be a rhamnolipid componentselected from a monorhamnolipid, a dirhamnolipid and combinationsthereof.

In part, the present invention can also be directed to a system orcomposite comprising an inventive composition and a substrate or mediumcomponent. Such a composition can be as described above or illustratedelsewhere herein. Without limitation, a substrate can be selected from afood or produce item, a packaging component (e.g., a film or wrapper)for a food or other perishable item, a fiber, cloth or clothing item, abuilding or construction component, a human tissue, a plant, plantsurface, soil, and garbage or refuse. In certain embodiments, such acomposition, whether liquid or gaseous, can be incorporated or otherwisein contact with such a medium, substrate or substrate surface.

In part, the present invention can be directed to an article ofmanufacture, such an article as can comprise a solid carrier componentand a volatile antimicrobial composition absorbed in, adsorbed on,coupled to or otherwise incorporated therewith. Such an antimicrobialcomposition can comprise propanoic acid; and a component selected from aC₂-about C₅ acid ester, an aldehyde and combinations thereof. In certainembodiments, such an acid ester can be selected from acetic acid esters,isobutyric acid esters and combinations thereof; and/or an aldehydecomponent can be selected from a C₂-about C₈ aldehyde component. Incertain such embodiments, an acid ester can be isobutyl isobutyrate; orsuch an aldehyde component can be benzaldehyde. Regardless, such anantimicrobial composition can be incorporated with a carrier componentcomprising a clay. In certain such embodiments, such a carrier componentcan comprise a bentonite clay. Regardless, such a composition cancomprise one or more optional components or adjuvants, including but notlimited to a rhamnolipid component.

Alternatively, such an article of manufacture can be considered with anincorporated antimicrobial composition as can comprise propanoic acidand a C₂-about C₅ acid ester comprising at least one of an alkylcarbonylgroup, RC(O)—, wherein R comprises an isopropyl, (CH₃)₂CH—, moiety, andan alkoxy group, —OR′, wherein R′ comprises an isopropyl, —CH(CH₃)₂,moiety. In certain embodiments, such an acid ester can be selected fromisoamyl acetate, isobutyl isobutyrate and a combination thereof. Incertain such embodiments, such an antimicrobial composition can consistof propanoic acid and isobutyl isobutyrate. In certain other suchembodiments, such a composition can consist of propanoic acid, isoamylacetate and benzaldehyde. Regardless, such a solid carrier component cancomprise a clay.

Accordingly, such an article can comprise a solid carrier componentcomprising a bentonite clay, and an antimicrobial compositionincorporated therewith. Without limitation, such an antimicrobialcomposition can be selected from a composition consisting essentially ofpropanoic acid and isobutyl isobutyrate; and a composition consistingessentially of propanoic acid, isoamyl acetate and benzaldehyde.

In part, the present invention can also be directed to an article ofmanufacture comprising granules of a solid carrier component and anantimicrobial composition incorporated therewith. Such a composition cancomprise a C₂-about C₅ acid component; at least one C₂-about C₅component isolatable from a volatile by-product of an isolated cultureof Muscodor crispansgrown on potato dextrose agar; and a componentselected from at least one C₂-about C₅ acid ester, an aldehyde andcombinations thereof. As relates to such an article, suchcomposition-incorporated solid carrier component granules can beprovided in a vapor-permeable enclosure.

In certain embodiments, such solid carrier and antimicrobialcompositions can be as discussed above or illustrated elsewhere herein.In certain such embodiments, such an antimicrobial composition can beabout 0.01 wt. % to about 10.0 wt. % of such an article. In certain suchembodiments, such a composition can be about 0.20 wt. % to about 10.0wt. %. In yet other embodiments, such a composition can be about 1.0 wt.% to about 3 wt. % of such an article. Without limitation as to solidcarrier component or antimicrobial composition incorporated therewith,such an enclosure can comprise a woven mesh and/or non-woven material ascan be configured as a flexible bag or pouch. Regardless, such anarticle of manufacture can be provided in a container with a perishablefood item.

Accordingly, this invention can also be directed toward a method ofmicrobial or insect treatment, prevention, inhibition, eradicationand/or to otherwise affect microbial or insect activity. Such a methodcan comprise providing a composition of this invention, including butnot limited to one or more compositions of the sort illustrated herein;and contacting a microbe or insect or an article/substrate capable ofsupporting microbial or insect activity with such a composition in anamount at least partially sufficient to affect microbial or insectactivity. Such a microbe (e.g., a fungus, bacterium or virus) or insectcan be in a medium, on or about a surface of a substrate of the sortdiscussed above. Accordingly, such contact can be direct and/or uponvolatilization of such a composition. Regardless, such treatment can beactive with respect to microbial or insect presence and/or prophylactic.As illustrated elsewhere herein, treatment can be considered in thecontext of microbial or insect death and/or inhibited growth oractivity.

In part, the present invention can also be directed to a method ofaffecting microbial activity. With respect to such a method, the presentinvention can comprise providing an article of the sort described aboveor illustrated elsewhere herein; and contacting the vapor of anantimicrobial composition of such an article with a microbe and/or afood item capable of supporting microbial activity, such a compositionas can be in an amount sufficient to affect microbial activity. Incertain embodiments, such a food item can comprise post-harvest produce.Together with an article of this invention, such produce as can beoptionally introduced to a container at a point along a produce supplychain. Without limitation, produce introduction can be at a point ofharvest, a point of processing, a point of wholesale distribution, apoint of retail sale, and combinations thereof. Regardless of produce orpoint of introduction, such an antimicrobial composition can be asdescribed above or illustrated elsewhere herein.

As discussed below and illustrated by several non-limiting examples,this invention can comprise one or more acid salts. Accordingly, inpart, the present invention can be directed to one or more compositionscomprising a propanoic acid component; and a component selected from aC₄-about C₆ acid salt component, a C₂-about C₅ acid ester component, aC₂-about C₈ aldehyde component and combinations thereof. In certainembodiments, such an acid salt component can be selected from salts ofisobutyric acid, salts of citric acid and combinations thereof. Incertain such embodiments, such an acid salt component can be selectedfrom salts of isobutyric acid and combinations thereof. Withoutlimitation, such a salt can be selected from potassium and ammoniumsalts of butyric acid. Regardless of the presence of an acid saltcomponent, such an ester component can be selected from esters of a C₄acid and combinations thereof. Likewise, regardless of the presence ofan acid salt and/or ester component, such an aldehyde component can bebenzaldehyde. In certain other embodiments, regardless of the presenceof an acid salt component, ester component and/or aldehyde component,such a composition can comprise a C₂-about C₆ acid component in additionto propanoic acid. In certain such embodiments, such an additional acidcomponent can be selected from acetic acid, isobutyric acid, citricacid, and combinations thereof.

Without limitation, such a composition can comprise propanoic acid andat least one C₄ acid salt. In certain embodiments, such an acid salt canbe selected from potassium and ammonium salts of isobutyric acid. Incertain such embodiments, such a composition can comprise an acidcomponent in addition to propanoic acid. Such an additional acidcomponent as can be selected from acetic acid, isobutyric acid, citricacid and combinations thereof. In certain other embodiments, such acomposition can comprise propanoic acid and at least one C₂-about C₅acid ester component. Certain such embodiments can comprise at least oneC₄ acid ester. Regardless, such a composition can comprise an acidcomponent in addition to propanoic acid, such an additional acidcomponent as can be selected from acetic acid, isobutyric acid, citricacid and combinations thereof.

In part, the present invention can also be directed to compositionscomprising propanoic acid and at least one C₄-about C₆ acid saltcomponent. In certain embodiments, such an acid salt component can beselected from salts of isobutyric acid, salts of citric acid andcombinations thereof. In certain such embodiments, such an acid salt canbe a salt of isobutyric acid. Without limitation, such an acid saltcomponent can be selected from potassium and ammonium salts ofisobutyric acid, and combinations thereof. Regardless of the identity ofsuch an acid salt component, such a composition can comprise an acidcomponent in addition to propanoic acid, such an additional acidcomponent as can be selected from C₂-about C₆ acids and combinationsthereof. In certain embodiments, such an additional acid component canbe selected from acetic acid, isobutyric acid, citric acid andcombinations thereof. Without limitation, such a composition can beselected from a composition consisting essentially of propanoic acid anda salt of isobutyric acid; and a composition consisting essentially ofpropanoic acid, a salt of isobutyric acid, and at least one of aceticacid and citric acid.

As discussed above and illustrated below, such compositions can beincorporated into an article of manufacture. Accordingly, in part, thepresent invention can be directed to an article of manufacturecomprising one or more compositions, of the sort discussed above,comprising propanoic acid. In certain embodiments, such an article canbe selected from a human food product, an animal food product, an animalcare product, a packaging product and a solid carrier component. Withoutlimitation, a solid carrier component can comprise a clay. In certainother embodiments, such a human food product can be selected fromprocessed foods. Various such articles are illustrated below, includingbut not limited to cheese and related dairy products.

In accordance with certain embodiments of this invention, compositionscomprising certain food and flavor compounds (FFCs) are especiallyinhibitory and/or lethal to certain pathogenic fungi, bacteria and othermicrobes of agricultural, medicinal, or commercial or industrialconcern. Such compositions can be distinguished over any previousmixture containing biologically derived compounds: for instance, thepresent compositions do not contain any naphthalene or azulene (non-GRAScompounds) derived substances. Conversely, such compositions cancomprise a mixture of organic compounds, each of which otherwiseconsidered (i.e., GRAS) a food or flavoring substance.

The present invention demonstrates the nature of such compositions,their preparation and application to various items (e.g., withoutlimitation, food, fibers, implements and construction surfaces) topreserve their integrity and prevent destruction by various fungi (moldsand other microorganisms). Such compositions can also be applied tobuilding structures, plant parts and even clothing items for theirpreservation. Further, as demonstrated below, such a composition cannegatively affect Mycobacterium tuberculosis—the microorganism thatcauses tuberculosis—including at least 3 strains that are otherwise drugresistant.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Photographs illustrating the killing effect of the FFCs againstclinical cultures of drug resistant Mycobacterium tuberculosis afterexposure for 2 days.

FIG. 2. A series of photographs illustrating the prevention of fungalgrowth (mold) on cheese by several methods employing the FFCs.

FIG. 3. The protective effect of the FFCs on yams in storage in thepresence of 0.2 ml of an FFC composition for 2 days. The yams were thenphotographed after 10 days. (The test is on the left and the control ison the right.)

FIG. 4. The protective effect of the FFCs from the decay of garbage for10 days held at 30° C.

FIG. 5. Demonstrating effect against tomato rot/wilt, on the left is thecontrol plate of C michiganense, and on the right is the plate treatedwith 20 microliters an FFC composition of this invention.

FIG. 6. Demonstrating effect of an FFC composition of this inventionincorporated into a skin cream product.

FIGS. 7A-B and 8 illustrate structures of several non-limiting,representative monorhamnolipid and dirhamnolipid compounds, inaccordance with certain non-limiting embodiments of this invention.

FIG. 9 provides two embodiments of a rhamnolipid component, designatedR1 and R2 for the respective mono- and dirhamnolipid structures, whichcan be used alone or in combination of one with the other, as describedin several of the following examples, in accordance with certainnon-limiting embodiments of this invention.

FIG. 10 provides alternate nomenclature and structures of FFCs useful inconjunction with various antimicrobial compositions, in accordance withcertain non-limiting embodiments of this invention.

FIGS. 11A-B provide digital images of (A) post-harvest produce preservedover 7 days in the presence of bentonite granules impregnated with anantimicrobial composition of this invention; and, by comparison, (B) acontrol system showing spoilage after 7 days in the presence of granuleswithout an incorporated antimicrobial composition.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

As illustrated by several non-limiting embodiments, this inventionrelates to the use of a new species of Muscodor and/or its volatileby-products and the development of non-natural, laboratory-prepared,biomimetic compositions comprising common food and flavor compoundsthat, when incorporated into various media, applied to surfaces, orintroduced to an atmosphere, space or volume, bring about adecontamination of the desired surface medium or volume of otherwiseunsightly, harmful, and/or pathogenic microorganisms including plantfungi and the causal agent of tuberculosis. The invention has extremelyimportant implications and applications to modern agriculture, humanmedicine, food sciences, and industry. The compositions of thisinvention are not obvious as having antimicrobial properties given thefact that no one individual ingredient, in and of itself, isbiologically active. A synergistic combination of component ingredientsmanifests the full potential antimicrobial activity.

With respect to the use of such a Muscodor species, a volatileby-product thereof or a non-naturally-occurring biomimetic compositioncomprising FFCs, contact can be direct or by exposure to a vaporassociated with such a species, by-product of biomimetic composition. Asillustrated below, in the context of certain embodiments, while vaporexposure can inhibit growth, direct microbial contact may be requiredfor bacterial or fungal death.

Regardless of mode of contact, the compositions of this invention can belaboratory-made, comprising chemically-synthesized components,naturally-derived components or a combination of such synthetic andnatural components. Regardless, such compositions can be biomimetic withrespect to the effect of a Muscodor by-product on a particular bacterialor fungal species. Alternatively, such a composition, by relativeconcentration or selection of any one or more FFC component thereof, candemonstrate varied or enhanced antimicrobial activity, as compared to aMuscodor fungal by-product.

In certain such embodiments, such a composition can be on, or as can beapplied to, a substrate or medium comprising a proteinaceous orcellulosic component which can, is capable of or does support microbegrowth. Without limitation, certain embodiments can comprise plants,plant components (e.g., roots, stems, leaves or foliage, produce and thelike) and any originating shoots or seeds. In particular, withoutlimitation, such compositions can be on any plant produce, whethertermed a fruit, vegetable, tuber, flower, seed or nut, whether before orpost-harvest. Certain such plants and/or produce therefrom arerecognized in the art, alone or collectively, as agricultural crops.Accordingly, in certain embodiments, a composition of this invention canbe on or applied to such a crop at any time during development,pre-harvest and/or post-harvest. Likewise, a composition of thisinvention can be applied to or incorporated into a beverage, food (e.g.,human, pet and/or animal) product or article of manufacture which can,is capable of or does support microbe growth.

In certain other embodiments of this invention, such a composition canbe on, or as can be applied to, a substrate or surface supporting orsupportive of microbe (e.g., yeast and/or fungi bacteria and/or virus)growth. Accordingly, such a substrate or surface can comprise anymaterial which can, is capable of or does support microbe growth. Suchsubstrates include but are not limited to wood, ceramics, porcelain,stone, plaster, drywall, cement, fabrics, leather, plastics and thelike.

In certain other embodiments, various compositions of this invention canbe on, in contact with, or as applied or administered to a substrate orsurface comprising mammalian or human tissue, including but not limitedto nails, hair, teeth or mouth, skin and other cellular material, in thecontext of a pharmaceutical or personal care or hygiene formulation forthe treatment or prevention of microbial growth or infection.Representative compositions are described, below, in terms at least inpart applicable to one or more other embodiments.

An endophytic fungus was recovered from inside the tissues of a wildpineapple plant (Ananas ananassoides) growing in the Bolivian Amazon.Ultimately, it was shown to produce a mixture of volatile compoundshaving antimicrobial activities. Using molecular techniques, the funguswas found to possess sequence similarities to members of the Muscodorgenus. These fungi are known to produce volatile organic compounds thatcan act as anti-microbials which are effective against both human andplant pathogens. Members of the Muscodor species have been identifiedutilizing methods such as Phylogenetic Character mapping employing 18SrDNA plus ITS-5.8S rDNA sequence analyses. The sequences found in thepresent fungus and other Muscodor spp. were BLAST searched in GenBank,and compared to other fungi (Bruns et al., 1991; Reynolds and Taylor1993; Mitchell et al., 1995; Guarro et al., 1999; Taylor et al., 1999).Ultimately it was determined that these isolates are related to Xylaria(Worapong et al., 2001a&b). All isolated taxa that belong to Muscodorhave similar characteristics, such as growing relatively slowly,possessing a felt-like mycelium, producing biologically active volatilecompounds, and causing no harm to the plants in which they originallyresided. Finally, they each share closely similar rDNA sequences (Ezraet al., 2004).

Although the present fungus shared all of the same common featuresmentioned above, there were a number of different aspects to the taxonwhich distinguished it from all other Muscodor spp. and isolates. Asillustrated more fully in the following examples, these uniquecharacteristics support establishment of the present fungus as a newspecies. The name proposed for this novel endophytic fungus is Muscodorcrispans.

As analyzed by GC/MS, the isolated fungus produced alcohols, esters andsmall molecular weight acids, in the gas phase, when grown on potatodextrose agar (PDA). As shown in Table 1, below, such compounds includepropanoic acid, 2-methyl; 1-butanol, 3-methyl, acetate; 1-butanol, andethanol. Neither naphthalene nor azulene derivatives (non-GRAScompounds) were produced by this organism when grown on PDA,distinguishing it from all other Muscodor spp. studied thus far. Theodor produced by the fungus becomes noticeable after about 1 week andseems to increase with time up to and including at least three weeks. Asillustrated below, the volatiles of this fungus possess inhibitory andlethal bioactivity against a number of plant and human pathogens usingthe standard bioassay technique (Strobel et al., 2001).

TABLE 1 Retention Time Min. Compound MW 2:05 Acetaldehyde 44.03 3:40Ethyl Acetate 88.05 3:51 2-Butanone 72.06 4:08 Propanoic acid,2-methyl-, methyl ester 102.07 4:18 Ethanol 46.04 5:29 Acetic acid,2-methylpropyl ester 116.08 6:39 Propanoic acid, 2-methyl-,2-methylpropyl ester 144.12 6:46 1-Propanol, 2-methyl- 74.07 6:522-Butenal, 2-methyl-, (E)- 84.06 7:12 1-Butanol, 3-methyl-, acetate130.10 8:18 Hexane, 2,3-dimethyl- 114.14 8:21 Propanoic acid, 2-methyl-,2-methylbutyl ester 158.13 8:31 1-Butanol, 3-methyl- 88.09 13:37 Propanoic acid, 2-methyl- 88.05 14:41  Formamide, N-(1-methylpropyl)-101.08 16:44  Acetic acid, 2-phenylethyl ester 164.08 20:44 Cyclohexane, 1,2-dimethyl-3,5- 192.19 bis(1-methylethenyl)-

As discussed above, the present invention includes use of M. crispansand/or a volatile by-product thereof in conjunction with anon-indigenous medium, substrate and/or volume for antimicrobial effect.Such use and/or applications can be as described herein or as wouldotherwise be understood by those skilled in the art, including but notlimited to use and application of the sort described in U.S. Pat. No.6,911,338, the entirety of which is incorporated by reference.

Alternatively, a wide range of natural and synthetic biomimeticcompositions can be used with comparable or enhanced effect or, asevidenced by one or more embodiments, to provide results heretofor notavailable through use of either the fungus or its volatile by-product.As a departure from the prior art and the by-product of M. crispans,such antimicrobial compositions can comprise food and flavor compoundsgenerally recognized as safe for human use and consumption.Representative thereof, several non-limiting biomimetic compositions areprovided in Tables 2-7, below. Various other compositions can comprisecombinations of compounds selected from any one or more of Tables 2-7.(See, e.g., examples 52-56.) Alternatively, any such composition cancomprise a component compound in addition to or as replacement for anycompound listed, to enhance volatility or modify any other end-use orperformance property. In certain such compositions, such a replacementor additional compound can have a GRAS designation and/or be sodesignated at levels utilized—such compositions as can be consideredessentially free of any component or material that would not begenerally recognized as safe (GRAS) under the applicable United StatesCode of Federal Regulations. Such compositions can, alternatively,include a component found in a volatile by-product of M. crispans and/ornot in a volatile by-product of another Muscodor sp.

Each such compound can be provided within an effective concentration orpercentage range and is either commercially available or can be preparedby those skilled in the art. With regard to the latter, fermentationtechniques can be used to naturally prepare and isolate such compounds.Alternatively, such compounds can be chemically synthesized. Withrespect to several non-limiting embodiments of this invention, eachcompound of Tables 2-7 can be obtained as a fermentation product, suchproducts and corresponding compositions as are available under theFlavorzon trademark from Jeneil Biotech, Inc. of Saukville, Wis.

TABLE 2 A biomimetic composition of this invention comprising: CompoundAcetaldehyde Ethyl Acetate 2-Butanone Propanoic acid, 2-methyl-, methylester Ethanol Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid Acetic acid, 2-phenylethyl ester

TABLE 3 A biomimetic composition of this invention comprising: CompoundAcetaldehyde Ethyl Acetate 2-Butanone Propanoic acid, 2-methyl-, methylester Ethanol Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid, 2-methyl- Acetic acid,2-phenylethyl ester Propanoic Acid

TABLE 4 A biomimetic composition of this invention comprising: CompoundAcetaldehyde Ethyl Acetate 2-Butanone Propanoic acid, 2-methyl-, methylester Acetic Acid Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid, 2-methyl- Acetic acid,2-phenylethyl ester

TABLE 5 A biomimetic composition of this invention comprising: CompoundAcetaldehyde Ethyl Acetate Acetic Acid Propanoic acid, 2-methyl-, methylester Ethanol Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid, 2-methyl- Acetic acid,2-phenylethyl ester

TABLE 6 A biomimetic composition of this invention comprising: CompoundAcetaldehyde Ethyl Acetate Propanoic Acid Propanoic acid, 2-methyl-,methyl ester Ethanol Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid, 2-methyl- Acetic acid,2-phenylethyl ester

TABLE 7 A biomimetic composition of this invention comprising variouscombinations of compounds selected from or comprising the followingcompounds: % Compound about 0.1 - about 10 Acetaldehyde about 0.5 -about 25 Ethyl Acetate about 0.1 - about 15 2-Butanone about 4 - about99 Propanoic acid, 2-methyl-, methyl ester about 1.5 - about 40 Ethanolabout 0.1 - about 10 Acetic acid, 2-methylpropyl ester about 0.1 - about15 Propanoic acid, 2-methyl-, 2-methylpropyl ester about 0.1 - about 101-Propanol, 2-methyl- about 0.5 - about 25 1-Butanol, 3-methyl-, acetateabout 0.5 - about 25 Propanoic acid, 2-methyl-, 2-methylbutyl esterabout 2 - about 50 1-Butanol, 3-methyl- about 10 to about 99 Propanoicacid, 2-methyl- about 0.1 - about 10 Acetic acid, 2-phenylethyl ester

With respect to any FFC composition of this invention, it iscontemplated that any compound component thereof—including any compoundcomponent described referenced or inferred herein, such as but notlimited to any component in Tables 1-7 and 10 and structural isomersand/or carbon and methylene homologs thereof—can be present in an amountor a range separate and apart from any other compositional component.Accordingly, without limitation, each such compound component can bepresent in an amount of or a range of about 0.1 wt. %, (or less) about0.2 wt. %, about 0.3 wt. %, or about 0.4 wt. %, . . . or/to about 1.0wt. %, about 1.1 wt. %, about 1.2 wt. %, about 1.3 wt. %, or about 1.4wt. % . . . or/to about 2.0 wt. %, about 2.1 wt. %, about 2.2 wt. %,about 2.3 wt. %, or about 2.4 wt. % . . . or/to about 3.0 wt. %, about3.1 wt. %, about 3.2 wt. %, about 3.3 wt. %, or about 3.4 wt. % . . .or/to about 4.0 wt. %, about 4.1 wt. %, about 4.2 wt. %, about 4.3 wt.%, or about 4.4 wt. % . . . or/to 5.0 wt. %, about 5.1 wt. %, about 5.2wt. %, about 5.3 wt. %, or about 5.4 wt. % . . . or/to about 6.0 wt. %,about 6.1 wt. %, about 6.2 wt. %, about 6.3 wt. %, or about 6.4 wt. % .. . or/to about 7.0 wt. %, about 7.1 wt. %, about 7.2 wt. %, about 7.3wt. %, or about 7.4 wt. % . . . or/to about 8.0 wt. %, about 8.1 wt. %,about 8.2 wt. %, about 8.3 wt. %, or about 8.4 wt. % . . . or/to about9.0 wt. %, about 9.1 wt. %, about 9.2 wt. %, about 9.3 wt. %, or about9.4 wt. % . . . or/to about 10.0 wt. %; and or/to about 10.1 wt. % . . .or/to about 20.0 wt. %, in accordance with such incremental variation;or/to about 20.1 wt. % . . . or/to about 30.0 wt. %, in accordance withsuch incremental variation; or/to about 30.1 wt. % . . . or/to about40.0 wt. %, in accordance with such incremental variation; or/to about40.1 wt. % . . . or/to about 50.0 wt. %, in accordance with suchincremental variation; or/to about 50.1 wt. % . . . or/to about 60.0 wt.%, in accordance with such incremental variation; or/to about 60.1 wt. %. . . or/to about 70.0 wt. %, in accordance with such incrementalvariation; or/to about 70.1 wt. % . . . or/to about 80.0 wt. %, inaccordance with such incremental variation; or/to about 80.1 wt. % . . .or/to about 90.0 wt. %, in accordance with such incremental variation;or/to about 90.1 wt. % . . . or/to about 99.9 wt. % (or more), inaccordance with such incremental variation. Likewise, withoutlimitation, any composition of this invention—regardless of identity oramount of any particular compound component or combination—can bepresent in amount (wt. %) or a wt. % range incrementally variable, asdescribed above, from 0.1 wt. % to 99.9 wt. % of any composition ormedium (e.g., within any range from about 0.1 wt. % to about 1.0 wt. %,about 2.0 wt. %, about 4.0 wt. % or to about 10.0 wt. %) thereinincorporated or article or substrate thereon applied.

Unless otherwise indicated, all numbers expressing amounts,concentrations or quantities of components or ingredients, propertiessuch as molecular weight, reaction conditions, and so forth used in thespecification and claims are to be understood as being modified in allinstances by the term “about.” Accordingly, unless indicated to thecontrary, the numerical parameters set forth in this specification andattached claims are approximations that may vary depending upon thedesired properties sought to be obtained by the present invention. Atthe very least, and not as an attempt to limit application of thedoctrine of equivalents to the scope of claims, each numerical parametershould at least be construed in light of the number of reportedsignificant digits and by applying ordinary rounding techniques.

Notwithstanding that the numerical ranges and the parameters settingforth the broad scope of this invention are approximations, thenumerical values set forth and the examples are reported as precisely aspossible. Any numerical value, however, may inherently contain a certainerror resulting from the standard deviation found in a respectivetesting measurement.

The compositions and methods of this invention can suitably comprise,consist of or consist essentially of any compound component oramount/concentration thereof disclosed, referenced or inferredherein—including but not limited to any compound component in Tables 1-7and 10, together with any structural isomers thereof, carbon and/ormethylene homologs of any such alcohol component, aldehyde component,ketone component, acid component and/or ester component, whether theacid-derived and/or alcohol-derived moiety thereof. Regardless ofamount/concentration, each such compound component or moiety/substituentthereof is compositionally distinguishable, characteristicallycontrasted and can be used in conjunction with the present compositionsand methods separate and apart from another such componentamount/concentration or another compound component (ormoiety/substituent) or amount/concentration. Accordingly, it should beunderstood that the inventive compositions and/or methods, asillustratively disclosed herein, can be claimed, practiced or utilizedwith change in amount or concentration in the absence of any onecomponent compound (or moiety and/or substituent thereof), such compound(or moiety/substituent thereof) or amount/concentration thereof whichmay or may not be specifically disclosed, referenced or inferred herein,the change or absence of which may or may not be specifically disclosed,referenced or inferred herein.

In preferred embodiments, a biologically effective composition of suchFFCs (prepared as a liquid mixture) is readily volatilized at roomtemperature and diffuses throughout an enclosed space to effectivelyinhibit and/or kill unwanted contaminating fungi (molds) on surfacesthat are desired to be free of such harmful microbes. The mixture maybeapplied as a spray (e.g., can with ingredients under pressure) or simplyplaced in a container and allowed to evaporate in the closed containeror sealed bag.

Regardless, the FFC compositions of this invention can be incorporatedinto a variety of end-use compositions, limited only by application.Such compositions include but are not limited to those directed tohuman/animal food or nutrient, personal hygiene, healthcare,agricultural, industrial, residential, medical and consumerapplications. In certain non-limiting embodiments, an FFC compositionand/or component(s) thereof can be present at about 0.1 wt. % or less toabout 99.9 wt. % or more of a particular end-use composition. Such levelof incorporation is limited only by desired antimicrobial effect and/orformulation considerations.

The present FFC compositions, under effective dose levels, are effectivein killing many plant pathogens, fungi that can cause food spoilage,microbes that can cause major human diseases and microbes that can foulwork surfaces, homes and other buildings. A non-exclusive list of suchapplications is below:

1. For treatment of cheeses in storage or in preparation to controlunsightly mold contamination of surfaces and eventual spoilage of thecheese blocks.

2. For treatment of various plant parts in storage including roots,tubers, stems, seeds and other organs that may be eventually used forfood preparation of for planting and re-vegetation or agriculturalpurposes.

3. For use in decontaminating buildings that may either have moldysurfaces or be infested to a point that a mold problem may develop.

4. For use in the preservation of garbage whilst it is in shipment overlong sea hauls from one port to another for eventual fermentation intoenergy related products.

5. For the decontamination of soils that may harbor microbes that arepotential plant pathogens.

6. For the treatment of patients with tuberculosis and othermycobacterium infections.

7. For treatment to control nasal infections and to clear nasal passageways.

8. For combining with specifically designed polymers that can be used towrap and thus preserve materials including foods, fibers and other itemsfor longer term safe storage.

More generally, the compositions of this invention can be used toinhibit the growth of or kill an organism selected from the groupconsisting of a fungus, a bacterium, a microorganism and a range ofother microbes or pests. Using methods well known to those of skill inthe art, such a composition is contacted with the organism in an amountat least partially effective to kill or inhibit the growth of theorganism. Alternatively, it can be used to treat human or animal waste,e.g., as a component of a waste water or solid management or treatment.Such compositions also are useful to decontaminate human and animalwaste, e.g., decrease or remove bacterial and fungal contamination. Yetfurther, such a composition can be used to treat or prevent mold onbuilding materials and in buildings by contacting the building, thebuilding materials, or the spaces between the building materials with aneffective amount thereof or vapors therefrom. For the purpose ofillustration only, an effective amount of such a composition can be usedalone or in combination with other fumigants or active agents in a roomor alternatively, during whole building fumigations.

When used in agricultural applications, the invention provides a methodfor treating or protecting fruit, seeds, plants or the soil surroundingthe plants from an infestation by an organism such as a fungus or abacterium, by contacting the microorganism with an effective amount ofone or more compositions of the sort described herein.

As discussed above, the present invention provides a method ofpreventing, treating, inhibiting and killing a bacterial, fungal, viraland/or other microbial infection. Such a method can compriseadministering to an article, animal/mammal or plant substrate, havingsuch an infection or growth or capable of supporting such an infectionor growth, an effective amount of an inventive composition—alone or ascan be incorporated into a composition or formulation. Accordingly, thepresent invention provides one or more compositions for pharmaceutical,personal (e.g., without limitation, cosmetic), industrial and/oragricultural use.

Microbial treatment can be achieved by contacting a bacterium, fungus,virus and/or other microbe with an effective amount of an inventivecomposition. Contacting may take place in vitro or in vivo. “Contacting”means that such a composition of this invention and such a microbe arebrought together in a manner sufficient to prevent, inhibit and/oreliminate microbial infection and/or growth. Amounts of such acomposition effective for such treatment may be determined empirically,and making such determinations is within the skill in the art Inhibitionincludes both reduction and elimination of microbial growth/activity.

Compositions of this invention may be administered to or contacted witha human, animal or plant, or article substrate surface by any suitableroute, including but not limited to orally or nasally (e.g., forpharmaceutical or personal care applications), and topically, as bypowders, granules, liquids, sprays, ointments, lotions or creams.Accordingly, compositions of the invention can comprise the respectivecomponent compounds in admixture with one or more acceptable carriersand, optionally, with one or more other compounds or other materials.Such a carrier should be “acceptable” in the sense of being compatiblewith the other components/ingredients of the formulation and notdeleterious to the desired effect or application.

Regardless of the route of delivery, treatment or administrationselected, the inventive compositions can be formulated to provideacceptable concentrations or dosage forms by conventional methods knownto those of skill in the art. The amount or concentration of any suchcomposition or component thereof, with or without a carrier, will varydepending upon the target microbe/substrate/article being treated, theparticular mode of administration/delivery and all of the other factorsdescribed above. The amount combined with a carrier material willgenerally be that amount of such a composition providing the lowest or aminimal concentration effective to produce a desired antimicrobialeffect.

The relative amounts or concentrations of an FFC composition and anotheroptional component in the compositions of the present invention can varywidely within effective ranges, as demonstrated in the examples thatfollow. The concentrations and/or doses utilized are preferably selectedto achieve an enhanced or increased activity over individual prior artcomponents alone and/or to maximize the activity of the composition atthe lowest effective component concentration(s). Accordingly, the weightratios and/or percent concentrations yielding such enhanced activitydepend not only on the specific FCC composition utilized, but on thespecific end-use application of the composition including, but notlimited to, climate, soil composition, nature of the substrate, articleand/or microbial host to be treated and/or potential exposure to aparticular microbe.

Methods of preparing formulations or compositions include the step ofbringing a composition of this invention, or one or more componentcompounds, into association with a carrier and, optionally, one or moreaccessory ingredients. In general, the formulations are prepared bybringing such a composition/component into association with a carrier(e.g., a liquid or finely divided solid carriers) and, if desired,shaping the product.

Formulations relating to the invention, whether a composition of thisinvention or any article of manufacture incorporating such acomposition, may be in the form of capsules, cachets, pills, tablets,powders, granules, paste or as a solution or a suspension in an aqueousor nonaqueous liquid, or as an oil-in-water or water-in-oil liquidemulsion, or as an elixir or syrup, or as pastilles (using an inertbase, such as gelatin and glycerin, or sucrose and acacia) and/or aswashes (e.g., mists, spray or mouth) and the like, each containing apredetermined amount of an inventive composition or components thereof.

In other solid such formulations (e.g., capsules, tablets, pills,dragees, powders, granules and the like), a composition of thisinvention can be mixed with one or more other active ingredients and/oracceptable carriers, such as sodium citrate or dicalcium phosphate,and/or any of the following: (1) fillers or extenders, such as starches,lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders,such as, for example, carboxymethyl-cellulose, alginates, gelatin,polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such asglycerol; (4) disintegrating agents, such as agar-agar, calciumcarbonate, potato or tapioca starch, alginic acid, certain silicates,and sodium carbonate; (5) solution retarding agents, such as paraffin;(6) absorption accelerators, such as quaternary ammonium compounds; (7)wetting agents, such as, for example, cetyl alcohol and glycerolmonostearate; (8) absorbents, such as kaolin and bentonite clay; (9)lubricants, such as talc, calcium stearate, magnesium stearate, solidpolyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and(10) coloring agents. In the case of capsules, tablets and pills, thecompositions may also comprise buffering agents. Solid compositions of asimilar type may also be employed as fillers in soft and hard-filledgelatin capsules using such excipients as lactose or milk sugars, aswell as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one ormore accessory ingredients. Compressed tablets may be prepared usingbinder (for example, gelatin or hydroxypropylmethyl cellulose),lubricant, inert diluent, preservative, disintegrant (for example,sodium starch glycolate or cross-linked sodium carboxymethyl cellulose),surface-active or dispersing agent. Molded tablets may be made bymolding in a suitable machine a mixture of the powdered activeingredient(s) moistened with an inert liquid diluent.

The tablets, and other solid forms of such compositions or articlesincorporating such compositions, such as dragees, capsules, pills andgranules, may optionally be scored or prepared with coatings and shells,such as enteric coatings and other coatings well known in theformulating art. They may also be formulated so as to provide slow orcontrolled release of the active ingredient(s) therein using, forexample, hydroxypropylmethyl cellulose in varying proportions to providethe desired release profile, other polymer matrices, liposomes and/ormicrospheres. These compositions may also optionally contain opacifyingagents and may be of a composition that they release the activeingredient(s) only, or preferentially, in a certain portion of thegastrointestinal tract, optionally, in a delayed manner. Examples ofembedding compositions which can be used include polymeric substancesand waxes. The active ingredient(s) can also be in microencapsulatedform.

Liquid forms for use or administration of this invention includepharmaceutically- or otherwise-acceptable emulsions, mixtures,microemulsions, solutions (including those in distilled or purifiedwater), suspensions, mists, syrups and elixirs. In addition to aninventive composition or compound component(s) thereof, a liquid formmay contain inert or other diluents commonly used in the art, such as,for example, water or other solvents, solubilizing agents andemulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,ethyl acetate, propylene glycol, 1,3-butylene glycol, oils (inparticular, cottonseed, groundnut, corn, germ, olive, castor and sesameoils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fattyacid esters of sorbitan, and mixtures thereof.

Besides inert diluents, such compositions and/or related articles canalso include adjuvants such as but not limited to wetting agents,emulsifying and suspending agents (e.g., sticker and spreader agents foragricultural application), coloring, perfuming and one or more otherpreservative agents. Suspensions can comprise suspending agents as, forexample, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol andsorbitan esters, microcrystalline cellulose, aluminum metahydroxide,bentonite, agar and tragacanth, and mixtures thereof.

Formulations of compositions of this invention and/or articles orproducts incorporating such inventive compositions for substrate ortopical (e.g., in the context of a personal care or hygiene product)administration/delivery of this invention, include powders, sprays,ointments, pastes, creams, lotions, gels, solutions, patches andinhalants. Such ointments, pastes, creams and gels may contain, inaddition to an inventive composition of this invention, excipients, suchas animal and vegetable fats, oils, waxes, paraffins, starch, tragacanthand other gums, cellulose derivatives, polyethylene glycols, silicones,bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.Likewise, powders and sprays can contain excipients such as lactose,talc, silicic acid, aluminum hydroxide, calcium silicates and polyamidepowder, or mixtures of these substances. Sprays can additionally containcustomary propellants such as volatile unsubstituted hydrocarbons, suchas butane and propane, or be delivered under positive air pressure.

Examples of suitable aqueous and nonaqueous carriers which may beemployed in the compositions of the invention include water, ethanol,polyols (such as glycerol, propylene glycol, polyethylene glycol, andthe like), and suitable mixtures thereof, vegetable oils, such as oliveoil, and organic esters, such as ethyl oleate. Proper fluidity can bemaintained, for example, by the use of coating materials, such aslecithin, by the maintenance of the required particle size in the caseof dispersions, and by the use of surfactants.

Depot forms of articles or products incorporating a composition of thisinvention can be made by forming microencapsule matrices of an activeingredient(s) in biodegradable polymers such aspolylactide-polyglycolide. Depending on the ratio of the activeingredient(s) to polymer, and the nature of the particular polymeremployed, the rate of release of the active ingredient(s) can becontrolled. Examples of other biodegradable polymers includepoly(orthoesters) and poly(anhydrides). Depot injectable formulationsare also prepared by entrapping the active ingredient(s) in liposomes ormicroemulsions which are compatible with body tissue.

Further, the compositions of the present invention and/or articles orproducts incorporating such a composition can comprise additionalchemical and/or biological, multi-site and/or single site antimycotic orantifungal, antibacterial and antimicrobial agents, of a similar and/ordifferent modes of action, as will be well known to those skilled in theart. Such agents can include, but are not limited to, potassiumbicarbonate, silica, copper or sulfur-based compounds and/or botanicaloils (e.g., neem oil). Further, such agents can include, but are notlimited to azoles; polyenes, such as amphotericin B and nystatin; purineor pyrimidine nucleotide inhibitors, such as flucytosine; polyoxins,such as nikkomycins; other chitin inhibitors, elongation factorinhibitors, such as sordarin and analogs thereof; inhibitors ofmitochondrial respiration, inhibitors of sterol biosynthesis and/or anyother fungicidal or biocidal composition known to those skilled in theart suitable for treating or preventing yeast or fungal, bacterial,viral and/or other microbial infections of plants, other substrates,animals and/or humans, or as can be found on or in any article ofmanufacture.

In certain embodiments, articles or products incorporating thecompositions of the present invention can also include one or morepreservative components known in the art, including but not limited to,sorbic or benzoic acid; the sodium, potassium, calcium and ammoniumsalts of benzoic, sorbic, hydroxymethyl glycinic, and propionic acid;and methyl, ethyl, propyl and butyl paraben and combinations thereof.

The compositions of this invention may contain a compound comprising anacidic or basic functional group and are, thus, capable of formingpharmaceutically- or otherwise-acceptable salts with pharmaceutically-or otherwise-acceptable acids and bases. The term“pharmaceutically-acceptable salts” refers to the relatively non-toxic,inorganic and organic acid and base addition salts of such compounds.Regardless, such salts can be prepared by reacting such a compound witha suitable acid or base. Suitable bases include the hydroxide, carbonateor bicarbonate of such an acceptable metal cation, ammonia, or such anacceptable organic primary, secondary or tertiary amine. Representativealkali or alkaline earth salts include the lithium, sodium, potassium,calcium, magnesium, and aluminum salts and the like. Representativeorganic amines useful for the formation of base addition salts includeethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine,piperazine and the like. Representative acid addition salts include thehydrobromide, hydrochloride, sulfate, phosphate, nitrate, acetate,valerate, oleate, palmitate, stearate, laurate, benzoate, lactate,phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate,napthalate, mesylate, glucoheptonate, lactobionate, and laurylsulphonatesalts and the like.

The compositions of the present invention can be used as aqueousdispersions or emulsions and are available in the form of a concentratecontaining a high proportion of an FFC (with or without a surfactant)composition, as can be diluted (e.g., water or another fluid component)before use. Emulsifiable concentrates or emulsions may be prepared bydissolving a composition of the present invention, together with anyother desired active ingredient, in a solvent optionally containing awetting or emulsifying agent and then adding the mixture to water whichmay also contain a wetting or emulsifying agent. Suitable organicsolvents include alcohols and glycol ethers. These concentrates shouldpreferably be able to withstand storage for prolonged periods and aftersuch storage be capable of dilution with water in order to form aqueouspreparations which remain homogeneous for a sufficient time to enablethem to be applied by conventional spray equipment.

Depending on the type of end-use application, articles or productsincorporating compositions of the present invention may also compriseany other required components including, but not limited to, solid orliquid carriers to facilitate application, surfactants includingbiosurfactants, protective colloids, adhesives, thickeners, thixotropicagents, penetrating agents, stabilizers, sequestrants, texturing agents,flavoring agents (e.g., for post-harvest or processed food/beverageapplications), sugars, colorants, etc., as will be well known to thoseskilled in the art.

For example, such compositions and/or related articles or products canbe used for agricultural purposes and formulated with such a carrier ordiluent. The compositions can be applied, formulated or unformulated,directly to the foliage of a plant, to seeds or to other medium in whichplants are growing or are to be planted, or they can be sprayed on,dusted on or applied as a cream or paste formulation, or they can beapplied as a vapor or as slow release granules. Application can be to,or proximate to, any part of the plant including the foliage, stems,branches or roots, or to soil surrounding the roots, fruit or vegetable(pre- or post-harvest) or to the seed before it is planted, or to thesoil generally, to irrigation water or to hydroponic culture systems.The inventive compositions can also be injected into plants or sprayedonto vegetation (including fruits and vegetables) using low volume orpressure or electrodynamic spraying techniques, or any other treatmentmethod known in the art or industry.

In certain embodiments, whether or not agricultural or related to foodprocessing, compositions and/or articles or products impregnated withand/or incorporating compositions of this invention may be in the formof dustable powders or granules comprising a solid diluent or carrier,for example, fillers (also such as animal or cat litter), kaolin,bentonite, kieselguhr, dolomite, calcium carbonate, talc, powderedmagnesia, fuller's earth, gypsum, diatomaceous earth, china clay andother impregnatable materials. Such granules can be preformed granulessuitable for application without further treatment. These granules canbe made either by impregnating pellets of filler with an inventivecomposition or another active ingredient or by pelleting a mixture ofthe active ingredient and powdered filler. For instance, compositionsfor dressing seed may include an agent (for example, a mineral oil) forassisting the adhesion of the composition to the seed; alternatively theactive ingredient can be formulated for seed dressing purposes using anorganic solvent. The compositions may also be in the form of wettablepowders or water dispersible granules comprising wetting or dispersingagents to facilitate the dispersion in liquids. The powders and granulesmay also contain fillers and suspending agents. Alternatively, thecompositions may be used in a micro-encapsulated form. They may also beformulated in biodegradable polymeric formulations to obtain a slow,controlled release of the active substance.

Regardless, such solid formulations comprising such an inventivecomposition can be provided in a range of products or articles invarying forms, shapes or moldings, including but not limited tocylinders, rods, blocks, capsules, tablets, pills, pellets (e.g., alsopet foods), strips, spikes and the like. Alternatively, granulated orpowdered material can be pressed into tablets or used to fill a range ofcapsules or shells. As discussed above, any such composition of thisinvention, whether formulated or unformulated, can be used alone,applied to a substrate or incorporated in a product or article ofmanufacture for a wide range of end-use applications, including but notlimited to pharmaceutical, personal, industrial and agriculturalcompositions and related methods of use.

Generally, a useful solid carrier component can comprise any materialthat is at least somewhat porous and/or can hold an aforementionedantimicrobial composition without undue swelling. Together withmaterials of the sort described above and elsewhere herein, examples ofsuch carrier components include silica gels, zeolites, calcium silicate,clays, activated charcoal, alumina, allophane, vermiculite, variousabsorbant and/or slow release polymers, and combinations thereof, aswould be understood in the art by those made aware of this invention. Incertain embodiments, such a carrier component can comprise one or moreclay materials—examples of which are useful in the context of thisinvention include, but are not limited to, attapulgite, montmorillonite,bentonite, hectorite, sericite and kaolin clays and mixtures thereof.Without limitation, bentonite clays, such as those comprising colloidalhydrated aluminum silicate containing varying quantities of iron, alkaliand/or alkaline earth metals, have been found especially useful.Bentonite clay materials and related processed products are commerciallyavailable from a number of sources, including American Colloid Companyof Arlington Heights, Ill., under the trade name Bentonite AE H,together with other sources identified herein or as would be known tothose skilled in the art.

Depending upon a particular article or end-use application, a volatileantimicrobial composition can be used neat or in combination with one ormore solvents or diluent components, such as but not limited to water,aqueous alcohol and other solvents compatible with such an antimicrobialcomposition and/or an FFC component thereof. As a further consideration,the release or volatility of such an antimicrobial composition can bevaried or adjusted by the presence of any one such solvent or diluentcomponent.

Production of various articles of this invention generally involvesadmixture of an antimicrobial composition of this invention and asuitable solid carrier component. Admixture can be performed using anytechnique known in the art. As but one consideration, mixing techniqueand duration should be sufficient to disperse an antimicrobialcomposition over or throughout a solid carrier component. The order ofadmixture can vary. For instance, a solid carrier component can beprovided or prepared, first, followed by addition of an antimicrobialcomposition. Alternatively, such an antimicrobial composition and allcomponents used to produce a carrier component can be admixed together.With regard to the latter, the components can be admixed neat or with asolvent (e.g., water and/or an alcohol), dispersant or one or more otheradjuvants. With respect to one formulation technique, the componentsused to produce a solid carrier and the antimicrobial composition can beadmixed, with the latter, optionally, as an aqueous solution. In yetanother embodiment, a powder form of a suitable carrier component can beadmixed with an antimicrobial composition and a suitable bindercomponent to provide an agglomeration of particles or granules ofsuitable dimension. Regardless of carrier identity, formulationtechnique or granule size, an antimicrobial composition can be presentat about 1.0-about 3.0 wt. % of such an article and associated carriercomponent.

An article of this invention can be arranged and presented inconjunction with a package or enclosure for release or volatilization ofan antimicrobial composition. A tote, lid, insert, covered tray or cup,carton, vial and other such enclosures known in the art can be used,providing sufficient article retention and antimicrobialrelease/vaporization therefrom. Examples of useful gas/vapor permeableenclosures include those configured in the shape of a flexible bag, packor pouch of a mesh or non woven fabric composed of a gas permeablematerial.

The articles described herein are useful in affecting microbialactivity, including inhibition of microbial growth, on and/or near afood item, thereby extending the shelf life of the food item. Towardthat end, such an article—whether alone, without an enclosure oroptionally presented in conjunction with a flexible bag or pouch—can bepositioned with respect to or dropped in a container for shipping,storage or display of a desired food item (e.g., without limitation,fruits, vegetables and other agricultural produce), such containerselected or designed depending on a particular food item. Articleplacement within such a container can be at any one or more points alonga corresponding food supply and distribution chain.

EXAMPLES OF THE INVENTION

The following non-limiting examples and data illustrate various aspectsand features relating to the compositions and/or methods of the presentinvention, including the preparation and use of antimicrobialcompositions comprising various component compounds, as are describedherein. In comparison with the prior art, the present compositions andmethods provide results and data which are surprising, unexpected andcontrary thereto. While the utility of this invention is illustratedthrough the use of several compositions and component compounds whichcan be used therewith, it will be understood by those skilled in the artthat comparable results are obtainable with various other compositionsand component compounds, as are commensurate with the scope of thisinvention.

Example 1a

Fungal Isolation. Several small stems of Ananas ananassoides were takenfrom a plant growing in the Bolivian Amazon in March of 2007. They werecollected in a savanna region adjoining the rainforest at 12°40′07″ Sand 68°41′58″ W and were immediately transported for analysis. Severalsmall (2-5 inch) pieces from the stems were cut and placed into 70%ethanol for 30 seconds under a laminar flow hood. A pair of steriletweezers was used to hold the stems separately in the flame to removeexcess alcohol. Then small pieces of inner tissue (beneath the bark)were excised and placed onto potato dextrose agar (PDA) with an activelygrowing M. albus isolate 620 on one side of the plate having a centerwell removed from it. Effectively, this technique can be used to selectfor other isolates of Muscodor (Worapong et al., 2001a&b). During anincubation period of two weeks, the Petri plates were examinedperiodically for any fungal growth. Once hyphae were observed, thehyphal tips were aseptically cut out of the agar and placed on freshPDA. The isolate was found in this manner. Several Petri plates (PDA)were used to determine if the fungus produced volatile antibiotics. Thisprocedure included removing a 1-inch section of the agar from the middleof the plate, plating a plug of the isolate on one side and allowing itto grow for several days, and then plating test organisms on the otherside of the gap.

Example 1b

Fungal Taxonomy. Fungus in nature is associated with A. ananassoides andis a deuteromycete belonging to mycelia sterilia. Fungal colonieswhitish on all media tested when left out of direct sunlight. Fungalcolonies pinkish on all media tested when put into direct sunlight.Spores or other fruiting bodies were not observed under any conditions.Hyphae (0.6-2.7 μm) commonly growing by branching, sometimes formingperfect coils (ca. 40 μm) and having cauliflower like bodies (3.5-14 μm)associated with them. Hyphae, newly developing, grow in an undulatingpattern when observed under all conditions with all of the media tested.Mycelium on PDA covers the plate in 3-4 weeks and produces a fruityodor.

Holotype: Endophytic on A. ananassoides. Collections were made in theBolivian Amazon in the Heath River area. The holotype comes from onlyone A. annisoides stem, collected in the Heath River country. A livingculture is deposited as Muscodor crispans in the living Montana StateUniversity mycological collection as acquisition number 2347(2/29/2008). Both 18S rDNA and ITS sequences of M. crispans (B-23) havebeen submitted to GenBank with the assigned serial number-EU195297.

Telomorph: The telomorph of this fungus may be found in Xylariaceae,based on the similarity of the 18S rDNA gene sequence data between M.crispans and the family Xylariaceae in the GenBank database (Bruns etal., 1991; Reynolds and Taylor 1993; Mitchell et al., 1995; Guarro etal., 1999; Taylor et al., 1999). The molecular data from the 18S rDNAgene sequences of M. crispans show a 100% homology with M albus isolate620.

Etymology: The genus name, Muscodor , is taken from the Latin word whichmeans musty. This is consistent with the quality of the odor produced bythe first three isolates of the genus. The species name is crispans,from the Latin meaning “curly, wavy.” The hyphae grow in regularundulating patterns.

Example 2a

Scanning Electron Microscopy. Scanning electron microscopy was performedon the isolate of example 1 after procedures described by Castillo etal. (2005). Agar pieces and host plant pieces supporting fungal growthwere placed in filter paper packets then placed in 2% gluteraldehyde in0.1 M sodium cacodylate buffer (pH 7.2 -7.4) with Triton X 100, awetting agent, aspirated for 5 minutes and left overnight. The next daythe pieces were washed six × 15-minute changes in water buffer 1:1,followed by a 15-minute change in 10% ethanol, a 15-minute change in 30%ethanol, a 15-minute change in 50% ethanol, five× 15-minute changes in70% ethanol, and were then left overnight or longer in 70% ethanol. Theywere then rinsed six times for 15 minutes in 95% and then three15-minute changes in 100% ethanol, followed by three 15-minute changesin acetone. The microbial material was critically point dried, goldsputtercoated, and images were recorded with an XL30 ESEM FEG in thehigh vacuum mode using the Everhart-Thornley detector. Hyphae weremeasured using Image J software available on-line.

Example 2b

Fungal Biology. The fungus produced a white mycelium on a water basedmedium. No fruiting structures or spores of any kind have been foundunder any lab conditions. Hyphae tend to intertwine to form coils. Otherspecies of Muscodor also have this tendency (Worapong et al., 2001a).Newly developing hyphae tend to grow in an undulating fashion ratherthan the typical straight pattern and commonly intertwine to make ropelike structures. This pattern of growth may prove useful as a diagnostictool in identifying this organism in in-vivo inoculation studies. Thefungus also produces cauliflower-like structures that seem to beconnected to the hyphae by small strands. These bodies do not germinateunder any conditions and thus appear not to be spores. This observationseems to be unique for Muscodor spp. and has not been noted as beingpresent in any other fungal species in general.

Example 3a

Fungal Growth and Storage. It was determined that the isolate did notproduce spores or any other fruiting bodies when several pieces ofcarnation leaves were placed on top of an actively growing isolate toencourage spore production, and no such structures were observed after aweek of incubation at 23° C. The fungus was also plated on severaldifferent media including Cellulose Agar (CA), Malt Agar (MA), and CornMeal Agar (CMA) to determine if spore production would be displayed.With the exception of a slower growth rate on some of the media, noother characteristics of the fungus appeared to be different, and nofruiting bodies or spores were observed.

Several methods were used to store the isolated fungus as a pureculture, one of which was the filter paper technique. The fungus wasalso allowed to grow on PDA, and then it was cut into small squareswhich were placed into vials containing 15% glycerol and stored at −70°C. The fungus was also stored at 4° C. by a similar method, usingdistilled water rather than glycerol. However, the most effective methodof storage was on infested sterile barley seed at −70° C.

Example 3b

Other, more classical features of the isolated M. crispans were alsoexamined and compared to M albus. Muscodor crispans produced a slowgrowing, dense, white colored mycelium on all media tested, unless itwas placed in direct sunlight, which caused the mycelium to develop alight pink color. This contrasts to M. albus that produces a whitishmycelium on all comparable media and conditions tested (Worapong et al.,2001 a). The young hyphae also grew in an undulating fashion, ratherthan the characteristic straight cable-like fashion as commonly observedwith M. albus (Strobel et al., 2001). No spores formed on any mediumincluding ones containing the host plant material or carnation leaves.Hyphae varied in diameter (0.8-3.6 μm) and were often intertwined tomake more complex structures and even hyphal coils (FIGS. 1-3). Thesehyphae were generally bigger than those of M. albus (Worapong et al.,2001a).

Example 4

Qualitative Analysis of Volatiles. The method used to analyze the gasesin the air space above a 10-day old culture of the mycelium growing inPetri plates was comparable to that used on the original isolate of theM. albus strain cz-620 (Strobel et al., 2001). First, a baked “SolidPhase Micro Extraction” syringe (Supelco) consisting of 50/30divinylbenzene/carburen on polydimethylsiloxane on a stable flex fiberwas placed through a small hole drilled in the side of the Petri platesporting the fungal growth. The fiber was exposed to the vapor phase ofthe fungus for 45 min. The syringe was then inserted into the splitlessinjection port of a Hewlett Packard 6890 gas chromatograph containing a30 m×0.25 mm I.D. ZB Wax capillary column with a film thickness of 0.50mm. The column was temperature programmed as follows: 30° C. for 2 minfollowed to 220° C. at 5° C./min. The carrier gas was ultra high purityHelium (local distributor), and the initial column head pressure was 50kPa. Prior to trapping the volatiles, the fiber was conditioned at 240°C. for 20 minutes under a flow of helium gas. A 30 second injection timewas used to introduce the sample fiber into the GC. The gaschromatograph was interfaced to a Hewlett Packard 5973 mass selectivedetector (mass spectrometer) operating at unit resolution. Dataacquisition and data processing were performed on the Hewlett PackardChemStation software system. Initial identification of compounds in thevolatile mixture produced by the fungus was made through librarycomparison using the NIST database.

Example 5a

Fungal DNA Isolation and Acquiring ITS-5.8S rDNA Sequence Information. A10 day old culture of the present fungus, growing on PDA, was used as asource of DNA after incubation at 25° C. using the Rapid Homogenization:Plant leaf DNA Amplification Kit (Cartagen; Washington, USA). Some ofthe techniques used were comparable to those used to geneticallycharacterize other M. albus isolates from Australia (Ezra et al., 2004).Squares of the cultured mycelia (0.5 cm²) were cut from one week oldcultures. The agar was scraped from the bottom of the pieces, in orderto exclude as much agar as possible. The pieces were placed into 1.5 mlEppendorf vials and incubated for about 10 minutes at −80° C. The DNAwas then extracted according to the instructions of the kitmanufacturer. Extracted DNA was diluted (1:9) in double-distilled,sterile water and 1 μl samples were used for PCR amplification. TheITS1, 5.8S ITS2 rDNA sequence was amplified by the polymerase chainreaction using the primers ITS 1 (TCCGTAGGTGAACCTGCGGG) and ITS4(TCCTCCGCTTATTGATATGC). The PCR procedure was carried out in a 14 μlreaction mix containing 1 μl DNA extracted from the fungal culture (1:9dilution), 0.5 μl primer ITS1 and 0.5 μl primer ITS4, 7 μl RedMix™ plusPCR mix with 1.5 mM MgCl₂ (GeneChoice, Inc., Maryland, USA) and 5 μlddH₂O PCR grade (Fisher Scientific, Wembley, Western Australia,Australia). The PCR amplification was performed in a Biometra personalcycler (Goettingen, Germany): 96° C. for 5 minutes followed by 35 cyclesof 95° C. for 45 seconds, 50° C. for 45 seconds and 72° C. for 45seconds, followed by a 72° C. cycle for 5 minutes. The PCR products wereexamined using gel electrophoresis, on a 1.3% agarose gel for 30 minutesat 100V with TAE buffer (Ge1XLUltra V-2 from Labnet International, Inc.,(Woodbridge, N.J., USA) or Wealtec GES cell system, from (Wealtec Inc.,Georgia, USA). Gels were soaked in a 0.5 μg ml-1 ethidium bromidesolution for 5 minutes and then washed in distilled water for 5 minutes.Gel imaging was performed under UV light in a Bio-Imaging System (model202D; DNR-Imaging Systems, Kiryat Anavim, Israel). A ˜500 bp PCR productwas purified using the UltraClean PCR Clean Up DNA Purification Kit (MOBIO Laboratories, Inc., California, USA). Purified products were sentfor direct PCR sequencing. Sequencing was performed on both strands ofthe PCR product using ITS 1 and ITS4 primers. Sequencing was performedusing DYEnamic ET terminators on a MegaBACE™ 1000 analysis system(Danyel Biotech Ltd., Rehovot, Israel). Sequences were submitted to theGenBank on the NCBI web site. Sequences obtained in this study werecompared to the GenBank database using the BLAST software on the NCBIweb site.

Example 5b

Molecular Biology of Muscodor crispans. The partial sequences of 18SrDNA, ITS1, 5.8S, and ITS2 have been demonstrated to be highly conservedregions of DNA and therefore very useful in the classification oforganisms (Mitchell et al., 1995). These molecularly distinguishingpartial sequences of M. crispans were obtained and compared with thedata in GenBank. After searching the 18S rDNA sequences, 525 bp of M.crispans were subjected to an advanced BLAST search. The results showed100% identity with 525 bp of M. albus (AF324337). Comparative analysisof the partial ITS 1&2 and 5.8S rDNA sequences of M. crispans hit ITS 1and 2 of M albus (AF324336), M roseus (AY034664), X. enteroleuca CBS651.89 (AF163033), X. arbuscula CBS 452.63 (AF163029), and Hypoxylonfragiform (HFR246218) at 95, 95, 90, 90, and 91% homologies,respectively.

Example 5c

While this invention is, in part, described in conjunction with isolatednovel fungi, it will be understood that variants and mutants of suchfungi—as would be understood in the art—are also contemplated in thecontext of the present invention. The terms “variant” and “mutant” canbe defined as provided in U.S. Pat. No. 6,911,338, the entirety of whichis incorporated herein by reference. Accordingly, this invention can bedirected to variant or mutant strains of M. crispans and correspondingcompositions thereof.

Example 6a

Bioassay tests for M. crispans against plant pathogens. The vapor of thevolatile by-product of M. crispans was tested for microbial inhibitoryactivity using a relatively simple test, as previously described in theliterature (Strobel, et al., 2001). A strip of agar (2 cm wide) in astandard PDA Petri dish was removed and M. crispans was inoculated andallowed to grow on one side of the plate for about a week. The testfungus or bacterium was then inoculated on the other side of the Petridish, using small plugs of agar for the fungi. The bacteria and yeastswere streaked onto the agar (1.5 cm long). The plate was then wrappedwith one piece of Parafilm and incubated at 23° C. for 48 hr. The effectof M. crispans on the growth of the test organisms and determined firstby verifying the presence or absence of growth where the inoculationshad taken place. If growth was observed, measurements of the diameter intwo locations of the fungal hyphae were taken. The biological activityof the vapor on bacteria and yeasts were assessed by estimating thedegree to which their growth was affected as percentage of growth on acontrol plate (Strobel et al., 2001). If no growth was observed, thetest organism was aseptically removed from the test plate and inoculatedonto a fresh PDA plate at some time point after exposure to the vapor inorder to ascertain viability of the test organism.

Utilizing the preceding methodology, when M. crispans was grown for 7-10days at 23° C. on PDA, the volatile by-product of the fungus proved tobe lethal to several fungi and bacteria. Gram-negative and Gram-positivebacteria, as well as yeasts and each of the major classes of fungi, wereutilized as test organisms. Most of the test organisms were 100%inhibited and died after a 2 day exposure to the by-product of M.crispans. (See Table 8.) Some of the test organisms did not succumb tothe volatiles of M. crispans after a two day exposure, but their growthwas significantly inhibited by the volatile by-product, and they werekilled after a four day exposure. Such organisms include Penicilliumroquefortii, Bipolaris sorokiniana, Stagonospora sp., and Fusariumoxysporum, among others.

TABLE 8 Effects of the M. crispans volatile by-product on many fungalpathogens of plants and some assorted bacteria. The inhibition valueswere calculated as % of growth inhibition as compared to an untreatedcontrol test organism. The tests were repeated at least 3 times withcomparable results. Inhibition of the test organisms was recorded 48hours after exposure to the fungus and vapor of the volatile fungalby-product. Inhibition (%) after Alive after Alive after 48 hours 48hours 96 hours Test organism exposure exposure exposure Alternariahelianthi 100 N N Aspergillus fumigatus 100 Y N Bacillus subtilis* 100 NN Bipolaris sorokiniana 100 Y N Botrytis cinerea 100 N N Candidaalbicans* 100 N N Cephalosporium gramineum 100 N N Ceratocystis ulmi 100Y N Cochiolobolus carbonum 100 N N Colletotrichum lagenarium 100 N NCurvularia lunata 100 Y N Drechslera teres 100 N N Drechsleratritici-repentis 100 N N Dreschlera portulacae 100 N N Escherichia coli*100 N N Fusarium avenaceum 100 N N Fusarium culmorum 100 N N Fusariumoxysporum 100 Y N Fusarium solani 50 Y Y Ganoderma sp. 100 Y NGeotrichum candidum 100 Y N Mycosphaerella fijiensis 100 N N Penicilliumroquefortii 100 Y N Phytophthora cinnamomi 100 N N Phytophthorapalmivora 100 N N Pythium ultimum 100 N N Rhizoctonia solani 100 N NSaccharomyces cerevisiae* 90-95 N N Sclerotinia sclerotiorum 100 N NStagonospora sp. 100 Y N Tapesia yallundae 100 N N Trichoderma viridae10 Y Y Verticillium dahliae 100 Y N Xanthomonas axonipodis p.v. citri*100 N N *Denotes that these organisms were streaked onto the test plate,and an indication of growth was made if colony development eventuallyoccurred. After appropriate exposure to the volatile by-product of M.crispans, the streaked area was compared to the growth on the controlplate and estimated for the % inhibition. Eventually each organism wasrestreaked on to a PDA plate to test for viability.

Example 6b

With reference to Table 8, the effect of the vapor of the volatileby-product of M. crispans on Botrytis is quite noticeable—especially onB. cinerea, the cause of gray mold of various plants. The inhibitory andkilling effects are also applicable to Botrytis allii which causes graymold neck rot of onion. Without limitation, such results suggest thepresent invention can be used effectively to modify the produce surfaceor storage atmosphere post-harvest to prevent mold and related issues.Likewise, such results support use of an FFC composition of thisinvention to treat onion (e.g., Vidalia onions), shallot and garlicproduce to prevent or control fungal growth.

Example 6c

Vapor from the volatiles of M. crispans are also effective against manyof the fungi causing decay and fungal growth on grain (e.g., corn,wheat, barley, rice, etc.), and this invention can be used inconjunction with various fruits and vegetables such as potatoes, beets,carrots sweet potatoes—such grains, fruits or vegetables, whether beforeor after harvest, in storage or shipment. Accordingly, the compositionsand methods of this invention can be applied to some of the majorfungi-related issues in the agriculture and food processing fields, andcan be used to target organisms such as but not limited to Alternaria,Cladosporium, Aspergillus, Penicillium, Diplodia, Fusarium andGibberella. (See, e.g., Table 8.)

Example 6d

Vapor from the by-product of M. crispans was effective against theMycosphaerella fijiensis fungus. (See, Table 8.) Accordingly, theinvention can be used as treatment for the fungus-associated BlackSigatoka disease of bananas and plantains.

Example 6e

Citrus canker disease threatens the very existence of the United Statescitrus industry. As shown in Table 8, vapor from the by-product of M.crispans effectively kills the canker-causing pathogen Xanthomonasaxonipodis p.v. citri. Such results suggest that FFC compositions andrelated methods of the present invention can be used effectively totreat seeds, seedlings, orchards, equipment or apparatus (including,e.g., worker equipment and clothing) and/or harvested fruit to prevent,inhibit or control canker disease. Example 7

As a follow up to the tests and results of Example 6, bioassay testswith the vapor of the volatile by-product of M. crispans were runagainst various other plant and human pathogenic fungi and bacteria.(See, Table 9, below). The fungus was grown on X-plates with PDA in onequadrant and incubated for 3-5 days at room temperature prior toinoculation with one or more test organisms. Control plates were made atthe same time of inoculation and grown on the same medium that wasoptimal for the individual test organism. The test organisms,Staphylococcus aureus 6538, Salmonella cholerasuis 10708, Escherichiacoli 11229, S. aureus ATCC 43300 (MRSA), and Vibrio cholerae ATCC 14035,were grown on Trypticase Soy Agar (TSA) in the three remaining quadrantsof the X plate. Three plates of each organism, with appropriatecontrols, were exposed to the vapor of the by-product of the fungus forapproximately two, four and six days at room temperature. In order tocheck for the viability of the test microbe, the fungus was thenphysically removed, and the control and test plates were placed in anincubator at 35±1° C. for a minimum of three to four days, with theexception of the Mycobacterium spp. which were incubated forapproximately one additional month. This was done in order to ascertainif the vapor of the by-product had inhibited or killed the testorganism, and viability of the organism was assessed. This same protocolwas followed for the Yersinia pestis and Bacillus anthracis, except thatthe exposure times were changed to 3 and 5 days, and Y. pestis wasincubated at 28±1° C. and in 5% CO₂ after exposure to the fungus. TheMycobacterium marinum ATCC 927 was grown on 7H11 agar (Difco Co) in theremaining three quadrants, using the previously stated protocol, andincubated at 33±1° C. All three replicates in the tests with eachorganism behaved identically.

For all Mycobacterium tuberculosis strains, also grown on 7H11, asection of agar was removed from the plate and the B-23 fungus (on PDA)was inserted. The plates were then inoculated from a broth culture.Control plates, where no fungus was present, were also inoculated. Ateach appointed time interval, a section of agar was removed from theplates and transferred to a separate and empty plate and placed in anincubator at 35±1° C. in order to determine the viability of themicrobe. The plates were placed in a plastic bag with moistened papertowels to prevent desiccation.

Pseudomonas aeruginosa 15442 and Burkholderia thailandensis 70038 wereboth grown on TSA agar. They were left at room temperature for theoptimal growth time for the organism and then moved to an incubator at35±1° C. and observed. It is to be noted that all tests using humanpathogens were conducted under strict and federally approved biosafetyconditions. All tests on human pathogens were repeated at least twice.

TABLE 9 Effects of the volatile by-product of M. crispans on variousGram+ and Gram− bacterial species. The exposure times were variedaccording to the particular organism of interest, and the viability ofthe test organism was determined after that period (listed as growth orno growth). Growth/No Growth (in Type of the presence Organism Cell WallExposure Time of M. crispans) Comments S. aureus 6538 Gram+ 2, 4 and 6days No growth S. cholerasuis 10708 Gram− 2, 4 and 6 days No growth P.aeruginosa 15442 Gram− 2 days Growth No visible difference betweenexposed and control plates. M. marinum ATCC 927 Acid-fast 2, 4 and 6days No growth B. thailandensis 70038 Gram− 2 days Growth No visibledifference between exposed and control plates. S. aureus ATCC 43300Gram+ 2, 4 and 6 days Growth No actual colonies (MRSA) formed, just aslightly filmy growth. E. coli 11229 Gram− 2, 4 and 6 days Growth Novisible difference between exposed and control plates. V. cholerae ATCC14035 Gram− 2, 4 and 6 days Growth Growth at 4 and 6 day exposuresappears to be slightly inhibited in comparison to control plates. Y.pestis 91-3365 Gram− 3 and 5 days No growth B. anthracis A2084 Gram+ 3and 5 days Growth Only a few colonies left after exposure and whenincubated, more grew. M. tuberculosis 3081 (resistant Acid-fast 2, 4, 7and 14 days No growth to isoniazid) M. tuberculosis Acid-fast 2, 4, 7and 14 days No growth 50001106 (resistant to streptomycin) M.tuberculosis Acid-fast 2, 4, 7 and 14 days No growth 59501228 (resistantto streptomycin/ethambutol) M. tuberculosis Acid-fast 2, 4, 7 and 14days No growth 59501867 (susceptible)

As shown in Table 9, all four acid-fast bacteria (Mycobacteriumtuberculosis strains) were killed after 2, 4, 7, and 14 day exposure toactively growing M. crispans (6-10 day old culture). Other bacteriawhich were killed after at least 2 days of exposure to M. crispans were:Staphylococcus aureus 6538, Mycobacterium marinum, Yersinia pestis, andSalmonella choleraesuis. Relatively somewhat or completely unaffected byexposure to M. crispans were the following: Pseudomonas aeruginosa,Burkholderia thailandensis, Staphylococcus aureus (MRSA), Escherichiacoli, Vibrio cholera, and Bacillus anthracis. However, the growth of S.aureus (MRSA) was only a slimy film rather than any distinct coloniesand thus it was affected by the VOCs of M. crispans. In addition, the B.anthracis plate had only a few colonies left on the exposure plate, butmore colonies grew after removal of M. crispans and subsequentincubation. Therefore, it is suspected that M. crispans vapor of theby-product is only effective against the vegetative cells of B.anthracis, but not against the spores. One month after the lastobservation time (14 days), no growth was observed on any of the platesexposed to the fungus, and growth was observed on all of the controlplates.

The experiments of the following examples illustrate various embodimentsof the inventive compositions and the utility thereof. Onerepresentative composition, without limitation as to component amount,concentration or ratio, is provided in Table 10. In certain embodiments,an amount of isobutryic acid can be replaced with propanoic acid at orabout the same level. In certain such or other embodiments, ethanol canbe replaced with acetic acid and/or 2-butanone can be replaced witheither acetic acid or propanoic acid. Also, various esters can bereplaced with isomers or homologs (e.g., without limitation, a3-methylbutyl ester, of propanoic acid, for a 2-methylbutyl esterthereof) of the esters listed. The results observed in the followingexamples were obtained with a composition of the compounds listed inTable 10. Consistent therewith, various other compositions can be usedwith comparable effect.

TABLE 10 A composition of food and flavor compounds useful in thecontrol of harmful microorganisms. Compound* in a Series of FFCsAcetaldehyde Ethyl Acetate 2-Butanone Propanoic acid, 2-methyl-, methylester Ethanol Acetic acid, 2-methylpropyl ester Propanoic acid,2-methyl-, 2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol,3-methyl-, acetate Propanoic acid, 2-methyl-, 2-methylbutyl ester1-Butanol, 3-methyl- Propanoic acid, 2-methyl- Acetic acid,2-phenylethyl ester *Each of these compounds occurs as a liquid at roomtemperature and can be used one with another to provide a liquidcomposition that readily volatilizes at room temperatures ortemperatures and pressures that otherwise permit volatilization.

An FFC Composition Used for Plant Disease Control. Example 8a

The relative ability of the FFCs to inhibit and kill test organisms wasmeasured. Test solutions were prepared by placing compounds in vials.The test mixture (20 microliters) was placed in a presterilized microcup(4×6 mm) located in the center of a Petri plate containing PDA. When notin use, the mixture was stored at 0° C. The test organisms (as mentionedin Table 9), freshly growing and excised on 3 mm³ agar blocks (at least3 agar blocks per test fungus), were placed 2-3 cm from the microcup andthe plate wrapped with two layers of parafilm. Measurements were made onmycelial growth from the edge of the agar blocks after a given timeperiod. However, in the case of Geotrichum candidum they were streakedand checked for new visible growth and viability by restreaking from theoriginal area of the agar plate that had been inoculated. Appropriatecontrols were also set up in which no test solution was placed into themicrocup. Tests on 20 μl of the FFC mixture were done at least twicewith comparable results.

Example 8b

Viability of the test microbes was made by aseptically removing thesmall agar block and placing it on a PDA plate and observing growthafter 1-3 days, or by re-streaking the Geotrichum candidum on a freshPDA plate. In this manner the viability of the microbes could beassessed. The results shown in Table lla indicate that the organismslisted below are all inhibited by the particular FFC composition and inmost cases killed by the exposure to them. These include Aspergillusniger, Penicillium sp. on cheese, Cercospora beticola, Verticillumdahaliae, Pythium ultimum, Phytophthora palmivora, Mycophaeraellafijiensis, Rhizoctonia solani, Aspergillus fumigatus, Geotrichumcandidum, Trichoderma viridi, Ganoderma sp., Curvularia sp., andBotrytis alli. Thus, when properly applied, an FFC composition has anability to control these pathogenic microbes. Such results indicate manyother pathogenic microbes can be either inhibited or killed by thismixture.

TABLE 11a A brief list of various plant pathogenic microbes and theirsensitivities to a representative FFC composition of this invention,with an exposure to 20 microliters of the mixture for 2 days at 23° C.on potato dextrose agar (PDA) in a parafilm sealed Petri plate. The agarplugs with the test microbe were eventually tested for viability afterremoval and placement on a regular Petri plate of PDA. Test OrganismEffect on Growth Alive or Dead after 48 hr Aspergillus niger No growthDead Penicillium sp. on cheese 95% inhibition Alive Cercospora beticolaNo growth Dead Verticillum dahaliae No growth Dead Pythium ultimum Nogrowth Dead Phytophthora palmivora No growth Dead Mycophaeraellafijiensis No growth Dead Rhizoctonia solani No growth Dead Aspergillusfumigatus No growth Dead Geotrichum candidum No inhibition AliveTrichoderma viridi 60% inhibition Alive Ganoderma sp No growth DeadCurvularia sp No growth Alive Botrytis alli No growth Dead

Example 8c

With reference to the data of Table 11 a, the activity profile of theFFC composition utilized indicates, in several instances, differentand/or enhanced antimicrobial effect, as compared to M. crispans andvapors of the volatile by-product thereof.

Example 8d

With reference to the preceding example and using comparable techniquesand procedures, the same pathogens were treated with propanoic acidvapors. Comparative results are shown in Table 1 lb, below, with thedata of Table 11 a reproduced in columns A and B, and observed effectsof propanoic acid, alone, provided in column C (% inhibition). At 20 μl,the amount of propanoic acid is comparable to a level of propanoic acidin certain embodiments of this invention. Propanoic acid isrepresentative of various lone compounds of the prior art known to havecertain antimicrobial effect. However, as demonstrated by comparativedata of Table 11b, the present compositions provide new and synergisticresults over and beyond that expected independently from a lone priorart component outside the context of this invention. As shown therein,while the prior art is at best merely inhibitory, the inventivecompositions eliminate (i.e., kill) many pathogens tested. Similarresults are obtainable by comparison with other such lone prior artcompounds/compositions.

TABLE 11b Comparative results showing improved antimicrobial activityover propanoic acid. Alive or Propanoic Dead Acid alone Effect on afterat 20 μl Test Organism Growth (A) 48 hr (B) After 24 hr (C) Aspergillusniger No growth Dead 0% Alive Penicillium sp. on cheese 95% inhibitionAlive Cercospora beticola No growth Dead 75% Alive Verticillum dahaliaeNo growth Dead Pythium ultimum No growth Dead 80% Alive Phytophthorapalmivora No growth Dead 100% ND* Mycophaeraella fijiensis No growthDead Rhizoctonia solani No growth Dead 80% Alive Aspergillus fumigatusNo growth Dead 0% Alive Geotrichum candidum No inhibition Alive 0% AliveTrichoderma viridi 60% inhibition Alive Ganoderma sp No growth DeadCurvularia sp No growth Alive Botrytis alli No growth Dead 0% Alive*100% inhibition, but viability not determined (ND).

Use of FFC Compositions for Treating Tuberculosis and Other HumanPathogens Example 9a

Four clinical drug resistant strains of M. tuberculosis isolates(5901867, 50001106, 59501228 and 3081) were exposed to an FFCcomposition. For each isolate, 10 μL of the culture was placed in themiddle of a 7H11 agar plate and then evenly spread across the wholesurface of the plate with a sterile plastic loop. Lids from 0.65 mlmicrocentrifuge tubes (micro caps) were cut off and autoclaved at 121°C. for 15 minutes inside an autoclavable tube with a screw-cap lid.Sterile forceps were used to remove a micro cap which was placed in thecenter of the inoculated plate. The control plates (one for eachisolate) did not receive a micro cap. Three plates for each isolate weremade and 5, 10, or 20 μL of the FFCs were placed in each of the threemicro caps of the respective plates. The plates were then placed into azip-lock sealed plastic bag with a damp paper towel and incubated at 36°C.±1° C. for approximately 28 days. After approximately 48 hours ofexposure, the micro cap was removed and disposed of and the plates werereturned to the incubator. The paper towels were frequently checked andre-moistened to prevent dehydration of the media. All of the controlplates had growth. All of the plates that were exposed to 5 and 10 μL ofvolatiles had growth. Only one isolate (50001106) exposed to 20 μL ofvolatiles had growth. It is to be noted that each isolate of Mtuberculosis is a clinical drug resistant strain of this organism. Allexperiments were carried out in US Government Approved BiosafetyLaboratory Conditions.

The control plates and the plates exposed to 5 and 10 μL of volatileswere plated on Apr. 14, 2008. The plates exposed to 20 μL of volatileswere plated on Apr. 22, 2008. All plates were checked multiple times.The final check was performed on May 19, 2008 and those organisms thatdid not survive are indicated on Table 12 as “--.”

TABLE 12 Inhibitory Effects of the FFCs in the growth of drug resistantM. tuberculosis Isolate of M. tuberculosis 5 μL 10 μL 20 μL 5901867 + +− 50001106 + + + 59501228 + + − 3081 + + −

The actual effects of an FFC composition of this invention on anotherstrain of TB are shown in FIG. 1: The killing effect of the FFCs on astrain (110107) of M. tuberculosis. The plate on the left is a controlplate that had not been treated with 20 microliters of the FFCs for 48hours, while the plate on the right was treated for 48 hours. Bothplates were then incubated for 28 days at 36° C. It is obvious fromthese experiments that the FFCs were able to kill ¾ of the drugresistant isolates of M tuberculosis. The prospect now exists for animaland eventually human trials using such FFC compositions in the treatmentof tuberculosis.

Example 9b

Consistent with the data of the preceding example, broader aspects ofthis invention can be demonstrated. Viable cultures and suitable mediaare prepared using materials and techniques well-known to those skilledin the art. For instance, exposure to an FFC composition of thisinvention (e.g., by direct contact of a liquid composition or by vaporstherefrom) can result in growth inhibition or death of the followingcoliform bacteria (gram stain and morphology): Escherichia coli (gramnegative, rod), Salmonella enteritidis (gram negative, rod), Pseudomonasaeruginosa (gram negative, rod), Staphylococcus aureus (gram positive,cocci) and Listeria monocytogenes (gram positive, rod).

Likewise, such results can also be obtained and demonstrated withvarious other gram-negative and/or gram-positive bacteria such as butnot limited to Bacillus cereus (gram positive, rod) and Clostridiumbotulinum (gram positive, rod).

Example 10

The IC₅₀ was calculated for some of the test organisms that were testedagainst an artificial composition to mimic the volatile by-product of M.crispans. (See, Table 1.) With reference to Table 12, all of the testorganisms were inhibited 100% with the utilization of 15 μL of theartificial mixture, and several of them were killed with as little as 10μL. Verticillium dahliae, Botrytis cinerea, and Aspergillus fumigatuswere not killed by even the largest volume of the mixture (30 μL), butall three were 100% inhibited with 10 or 15 μL of the test mixture. Themost sensitive organism was Pythium ultimum, which was killed with 10 μLand 100% inhibited with 2.5 μL thus it is the case that the IC₅₀ valuesdo not necessarily reflect the killing ability of the volatiles sinceboth P. ultimum and Botrytis cinerea possess virtually the same IC₅₀sbut one is killed and the other was not (Table 13).

TABLE 13 The IC₅₀s of the artificial mixture of the components of thevolatile by-product of M. crispans on various plant pathogens. Amountsof the mixture, ranging from 1 μL to 30 μL, were added to a sterileplastic well in the center of the test plate, and the pathogenicorganisms were placed around the edge of the plate. Viability wasassessed after 48 hours and compared to a control plate with no mixtureadded but with the sterile well in place. Any organisms which showed nogrowth after that period were determined to be 100% inhibited, whilethose which showed no growth after the 48 hours and no growth afterisolation onto PDA immediately following the 48 hour assessment wereconsidered dead. The IC₅₀ calculation was determined by dividing theamount of the artificial mixture required to cause 50% inhibition (inμL) by the total air space in the Petri dish (50 mL). Minimum volumeVolume to cause 100% to cause IC 50 Test Organism inhibition (μL) death(μL) (μL mL⁻¹) Pythium ultimum 2.0 10.0 0.030 ± 0.004 Phytophthoracinnamomi 5.0 30.0 0.056 ± 0.009 Sclerotinia sclerotiorum n/a >30  0.15± 0.016 Botrytis cinerea 10.0 >30 0.035 ± 0.004 Rhizoctonia solani 20.015.0 0.039 ± 0.006 Aspergillus fumigatus 2.0 20 0.031 ± 0.003Verticillium dahliae 5.0 >30 0.062 ± 0.004 Phytophthora palmivora 1.05.0 <0.02

Use of an FFC Composition for the Treatment of Garbage to ControlMicrobial Decay. Example 11

An artificial mixture of items, which would normally be considered asgarbage, was assembled into two ammo cartridge boxes. These itemsconsisted of waste cereal items, flower parts, meat wastes, newspaperfiber, and miscellaneous other wastes. Into one box was placed a smallbeaker containing 0.2 ml of the aforementioned FFC composition. Into theother box was placed a beaker with no FFCs. Both boxes were incubatedfor 10 days at 80° F. At the end of that time the boxes were opened andexamined. It was obvious that no decay had occurred in the box with theFFCs. On the other hand, the control box had completely turned to amassive amount of decay. The use of the FFC composition for garbagetreatment is an opportunity to save intact garbage form decay whilst intransit to facilities around the world that ferment the garbage intoenergy related products such as methane. FIG. 4 illustrates that the FFCcomposition protected the garbage from microbial decay under theconditions of this experiment.

Use of an FFC Composition for the Treatment of Cheese to Control FungalDecay Example 12

A vial containing 10 ml of the aforementioned FFC composition wasincorporated in or with and/or used to soak a piece of clear plasticSaran® wrap 10×10 inches. The plastic wrap was soaked in the FFCcomposition for 6 days, drip dried and then used as a wrapper over thecheese piece thoroughly inoculated with a cheese strain of Penicillumsp. In another experiment, the cheese piece was inoculated with thefungus then wrapped with regular Saran® wrap and then injected with 10microliters of the FFCs. The appropriate controls are indicated on theillustration above with Penicillium sp. alone, treated wrapper alone,the FFCs alone and control (no treatment). The experimental cheesepieces were incubated for 1 week at room temperature and then portionsof each cheese item was eat-tested by lab personnel. It is to be notedthat there was no adverse effects of storage in this manner with aprostitution of the taste of the cheese when compared to a newly cutfresh piece of cheese that had been stored in the refrigerator. Thetotally fungal infested cheese piece was not eaten. It is obvious fromFIG. 2 that use of an FFC composition under the wrapper or with thetreated wrapper caused virtually complete protection of the cheese piecefrom decay and colonization of the cheese by Penicillum sp. This wastrue with the treated wrapper and with the injection of 10 microlitersof FFCs under the plain Saran wrapped cheese alone.

Use of an FFC Composition for the Treatment of Food and Plant Parts(e.g., Plant Produce) to Control Fungal Decay Example 13a

Several yams were obtained for these experiments. It was thought thatthe surface contaminating microbes causing eventual decay would beplentiful enough for the inoculum. Thus, two yam pieces were placed in aplastic box with the lid sealed in the presence of a small beakercontaining 0.2 ml of the FFCs. The control box contained a beaker withno FFCs. The sealed boxes were then held at room temperature for 10 daysand then examined. It was obvious that no surface and deepercontamination of the treated yam pieces developed, while the controlyams developed multiple areas of surface blemishes and insipient decayas illustrated in FIG. 3: The untreated yam is on the left and the oneon the right has been treated with the FFCs. Note the large area offungal decay on the top end of the yam on the left.

Example 13b

As a related end-use application, an FFC composition and/or componentthereof can be applied to harvested fruit or vegetable produce tocompensate for removal of any natural, waxy or protective coatingthereon. For instance, harvested squash and similar produce, with cutstems, can be treated with an FFC composition (e.g., with sprayapplication) to control/inhibit microbial growth, improve marketabilityand extend shelf life.

Example 14

A synthetic FFC composition of this invention, in accordance withcompositions of the sort described in Tables 2-7 and 10, comparedfavorably with the use of live M albus for control of seedling diseasesof sugar beet (Beta vulgaris L.) caused by Pythium ultimum, Rhizoctoniasolani AG 2-2 and Aphanomyces cochlioides, and root-knot nematode,Meloidogyne incognita, on tomato (Lycopersicon esculentum). Thesynthetic composition provided control of damping-off equal to astarch-based formulation of the live fungus for all three sugar beetpathogens, and significantly reduced the number of root-knot galls ontomato roots. Rate studies with the FFC composition utilized showed thatconcentrations of 2 μl/cm³ and 0.75 μl/cm³ of a soil carrier/mediumcomponent provided good control of Rhizoctonia and Pythium damping-off,respectively, of sugar beet. A concentration of 5 μl/cm³ sand provided100% mortality in 24 h for M. incognita. By comparison, using in vitrostudies, this same rate of the biorational provided fewer root-knotgalls than an M. albus infested ground barley formulation applied at 5g/l of sand.

Example 15

Corynebacterium michiganese causes serious tomato loss through tissuewilt and rot. An authentic culture of this bacterium was streaked onnutirnet broth agar and a small cap was placed in the middle of theplate. Into the cap was placed 20 microliters of an artificial,lab-prepared FFC composition of this invention. A control platecontained no FFC composition. The plates were incubated for 24 hr., thenexamined. There was no growth of the bacterium on the FFC-treated plate.(See, FIG. 5.) As such, an FFC compositon of this invention can be used,without limitation, to treat tomato seeds, plants or produce.Alternatively, an FFC composition can be mixed with water as a pre-bedsoil drench.

Example 16

With reference to the preceding and consistent with several of theforegoing examples, a range of FFC compostions of this invention can beused either prophylactically or in the treatment of active diseasestates, such disease including, without limitation, diseases affectingsugar beet, tomato, onion, grain, banana and plantain, and citrus cropsamong others.

More generally, the present compostions and methods can be directed tothe treatment and enhanced viability of seeds, plants, produce and/orrelated food products—whether prophylactically or in the presence offungal or bacterial microbes, regardless of lifecycle stage (e.g.,zoospore, etc.), development, growth or extent of infection.Accordingly, as would be understood by those in the art, suchcompositions can comprise and/or be applied, irrespective of form (e.g.powder, granules, liquid, mist, suspension, vapor, pastes, gels,coatings, etc.), on the surface of or in contact with a seed, seedlingor plant (e.g., roots, stems, leaves, etc.) or produce therefrom (e.g.,either pre- or post-harvest).

Example 17

FFC compositions and/or components thereof, either alone or as can beincorporated into various other compositions, can be employed in avariety of end-use applications in the poultry, produce and relatedfood-processing industries. Several such non-limiting applications areprovided in the following examples.

Example 17a

An FFC composition of this invention, in accordance with compositions ofthe sort described in Tables 2-7 and 10, is used to treat a range of eggproducts, including but not limited to whole egg, and liquid whole egg,fortified whole egg, and liquid fortified whole egg, salt whole egg, andliquid salt whole egg, sugar whole egg, and liquid sugar whole egg, andblends of such products—whether or not liquid—with sugar, syrup solids,syrups, dextrose and dextrins and/or gums and thickening agents,together with scrambled egg mixes and liquid scrambled egg mixes,reduced cholesterol egg products and liquid products and blends thereof,and related products containing less than about 10% egg solids, shelleggs and egg components including but not limited to decholesterolizedegg yolk. Such terms will be understood by those skilled in the art andhave standard meanings in accordance with accepted industry andregulatory usage.

Example 17b

Likewise, various FFC compositions of this invention, including but notlimited to those utilizing propanoic acid in at least partialsubstitution for isobutryic acid, can be used in the preparation and/orpackaging of extended shelf life (ESL) liquid egg products, includingbut not limited to whole egg, scrambled mixes, egg yolk and egg whiteliquid products.

Example 17c

Likewise, various FFC compositions of this invention can be used in theprocessing of cracked, empty egg shells. As would be understood in theart, using available techniques and processing equipment, an FFCcomposition and/or a component thereof—alone or as incorporated as partof another composition—can be applied (e.g., sprayed on) to empty shellsbefore further processing, for instance into a nutraceutical product.Likewise, one or more compositions of this invention can be applied toor incorporated with or otherwise used to treat poultry carcass, meat ora related meat product, using apparatus and techniques known in the art.By extension, one skilled in the art would understand that the presentinvention can also be utilized with other types of animal carcass, meat,processed meat products and all other forms of animal flesh (e.g.,mammals, birds, fishes, snails, clams, crustaceans, seafood and otheredible species), as also illustrated in one or more of the followingexamples.

Example 17d

As an extension of the preceding example, such an FFC composition can beincorporated into such a processed nutraceutical product (e.g., herbaland spice capsules or tablets) to inhibit bacterial/fungal growth.

Example 17e

While the preceding examples illustrate various downstream processingapplications, the present invention can be utilized more widely in thecontext of egg and poultry production. Without limitation, FFCcompositions or related components of this invention can be introducedto any poultry or egg production facility and/or applied to anyequipment or machinery associated therewith. For instance, air orsurface treatment of a coop or growing/laying facility can control,reduce and/or inhibit airborne and surface-deposited contaminants andsubsequent microbial growth thereon.

Example 18

An FFC composition or one or more components thereof can be incorporatedinto a variety of other processed food products, including food productshaving a water activity otherwise supportive of microbial growth. Forinstance, such a composition or component can be incorporated intohumus, peanut butter and other such spreads, dips and mixtures. Relatingto the peanut growing and processing industries, compositions andrelated components of this invention can be applied to peanuts beforeand after the shells are cracked, after an initial peanut wash, to arelated processed product (e.g., peanut butter) and/or on packagingequipment and packing materials.

Example 19

Likewise, an FFC composition/component of this invention (e.g., one ormore of or compositions of Tables 2-7 and 10, above, or variations ofthe sort described therein) can be used as or incorporated into avariety of skin care or treatment products, regardless of formulation(e.g., lotion, ointment, cream, etc.).

Example 19a

For instance, acne is commonly caused by one or more bacterial speciesinvading skin follicles. Demonstrating further use of this invention, anaqueous formulation of a propanoic acid-substituted FFC composition ofthis invention was prepared and used to treat an adolescent male subjectpresenting age-related acne. One application every three days for threeweeks significantly reduced, by visual observation, the number andintensity of acne lesions.

Example 19b

Demonstrating another use of this invention in the context of a consumerand/or health care product, an FFC composition of this invention wasincorporated (at approximately 2% by weight) in a representative overthe counter skin cream preparation. With reference to FIG. 6, a PDAplate was prepared and incubated for one day with a control cream(without FFC component or composition), top left; a control creamcontaminated with bacterial cells, top right; “treated” cream with FFCcomposition, bottom left; and treated cream with bacterialcontamination, bottom right. As shown, bacterial growth in such a skincream product was prevented by incorporating a modest concentration ofan FFC composition of this invention.

Example 20

Likewise, this invention can be utilized in conjunction with a range oforal hygiene, care and treatment products. Without limitation, thefollowing examples demonstrate such use of a propanoic acid-substitutedFFC composition of the sort described above. Alternatively, variousother FFC compositions can be used, in accordance with compositions ofTables 2-7 and 10, above, or variations thereof as described elsewhereherein.

Example 20a

For instance, illustrating one such oral care/hygiene product, amouthwash/rinse product was formulated utilizing about 1% of such an FFCcomposition. Such a product was prepared by incorporation of such an FFCcomposition into a commercially-available, off-the-shelf mouthwash/rinseproduct. FFC compositions of this invention, regardless of concentrationor dose level, can also be incorporated into a tooth paste/gel orrelated gum, mouth, oral or dental care product.

Example 20b

Lichen planus (LP) is an autoimmune disease of the skin that can occurinside the mouth or on other mucous membranes. As membranes becomeunstable, bacteria or fungi can take up residence in these areas andcause pain, reddening, infection, bleeding and swelling of the tissues.In order to reduce the cause of extraneous involvement of bacteria inthis disease, a mouth wash product was prepared containing a 1% aqueoussolution of such an FFC composition. The mouth of the patient was rinsedtwice to three times daily for at least 3-4 minutes and then spit out.Photos were taken before the treatments were applied and after threeweeks of treatment. After 3 weeks, the results showed an almost totalreduction of gum reddening, accompanied by a nearly totally reduction ofmouth and gum pain as well as a return to near normal color of the gumsand other mucous membrane color. The patient reported a near-totalcessation of pain/bleeding and the most relief from LP, as compared toprior experience.

Example 20c

A 1% solution of the aforementioned FFC composition in an off-the-shelfmouth rinse was used to reduce dental plaque and treat other problemsarising from bacteria associated with oral problems. Daily use, with 3-4mouth rinses/day, for two months resulted in little or no dental plaquebuild-up. Gums that were initially recorded as red, swollen, and easilycaused to bleed (from notes actually taken by the dentist) now appearedas normal in color and did not bleed upon probing with the “explorer”instrument.

Example 20d

To confirm effectiveness of such an FFC composition, mouth spittleresulting from the previous example was placed on one side of a nutrientagar plate, spittle from a non-FFC commercial mouth rinse was placed onthe other side of the same plate, and non-rinse spittle was placed onanother plate. The spittles were then incubated for two days. Bycomparison: the non-rinse spittle had a high bacterial load; the non-FFCrinse spittle had, as expected, a reduced bacterial load; but theFFC-rinse spittle had no detectable bacteria.

Example 20e

In another example, an oral surgeon tested an FFC composition (e.g., as1% of a commercial rinse/wash product) prior to oral surgery. Thepatient placed non-treated spittle on an agar plate (nutrient agar),rinsed with the FFC-rinse solution and placed that spittle on anotheragar plate. After two-three days of incubation there were no bacterialcolonies on the FCC-rinse treated plate, indicating use before and afteroral surgery to treat or inhibit tooth or other oral infections.

Example 21

Mastitis in milk cows is caused by a complex of bacteria associated withthe udder. In accordance with various non-limiting embodiments of thisinvention an FFC composition or a rhamnolipid modified FFC compositionof the sort described below can be applied to the udder at the time ofmilking to reduce the prospect of bacterial infections and contaminationof milk product.

Example 22

Various FFC compositions of this invention can be used to reducemicrobial loads on industrial/medically important biofilms. With regardto the latter, items ranging from dental prostheses to artificialjoints, can be treated with an FFC composition of this invention beforesurgical implantation.

Example 23

FFC compositions of this invention can be used to control fungal andbacterial decay of clothing items especially those exposed to moistenvironments (i.e,. leathers, shoes, boots, straps, ties, belts). Forinstance, application of 0.2 ml of a 1% FFC composition of the sortdescribed above was placed in boots that had become totally wet. Theboots were enclosed to maintain the resulting vapors for a few hours,then exposed to dry air. The results showed no decay, and the bootsdried without a residual moldy smell.

Example 24

Compositions of the present invention can comprise various FFCcomponents and can be formulated as would be understood by those skilledin art made aware of this invention. Without limitation, regardless ofend-use application or treatment, one or more of the present FFCcomponents and/or related compositions can be incorporated into variousantibacterial or antimycotic compositions. Without limitation, such acomposition can comprise a rhamnolipid surfactant component—either aloneor in conjunction with an antibacterial and/or antimycotic component ofthe sort known in the art. With respect to the latter, such compostionscan comprise a syringomycin and/or a pseudomycin component.

More specifically, as would be understood by those skilled in the art, arhamnolipid component can comprise one or more compounds of the sortdescribed in U.S. Pat. Nos. 5,455,232 and 5,767,090, each of which isincorporated herein by reference in its entirety. Such a rhamnolipidcompound, whether presently known in the art or hereafter isolatedand/or characterized, can be of a structure disclosed therein or varied,as would also be understood by those skilled in the art. For example,without limitation, whether synthetically-derived or naturally occurring(e.g., from a Pseudomonas species or a strain thereof) in an acid formand/or as a corresponding acid salt, such a compound can be alkyl-and/or acyl-substituted (e.g., methyl and/or acetyl, respectively, andhigher homologs thereof) at one or more of the saccharide hydroxypositions. Likewise, whether in mono- and/or dirhamno form, any suchcompound can be varied by hydrophobic moiety. As a non-limiting example,with reference to FIGS. 7A and 7B, m and n can independently range fromabout 4 to about 20, regardless of whether such moieties are saturated,monounsaturated or polyunsaturated, whether the hydrophobic moiety isprotonated, present as the conjugate base with any counter ion orotherwise derivatized. Consistent with broader aspects of thisinvention, a rhamnolipid useful in such compositions is structurallylimited only by resulting surface active function and/or antimicrobialeffect in conjunction with an FFC composition of this invention.Accordingly, structural variations of the sort described inInternational Publication WO 99/43334 are also considered in the contextof this invention, such publication incorporated herein by reference inits entirety. See, also the non-limiting rhamnolipidcomponents/structures of FIGS. 8-9.

Without regard to antimicrobial or rhamnolipid identity, a carriercomponent of the inventive compositions can comprise a fluid selectedfrom, but not limited to, water, an alcohol, an oil, a gas andcombinations thereof. For instance, while such compositions areunlimited with respect to amount or concentration (e.g., wt. %) ofantimicrobial or rhamnolipid quantities, a carrier comprising waterand/or an alcohol can be used to facilitate desired formulation,shipping, storage and/or application properties, as well as effectiveconcentration and resulting activity.

Such rhamnolipid surfactant components, antimycotic components and/orrelated compositions include but are not limited to those described inco-pending application Ser. No. 11/351,572, in particular examples 9-15thereof, such application filed on Feb. 10, 2006 and incorporated hereinby reference in its entirety. Such rhamnolipid surfactant components,antimycotic components and/or related compositions can incorporate or beused in conjunction with one or more FFC components and/or FFCcompostions of the present invention. Such antibacterial and/orantimycotic components are known to those skilled in the art andcommercially available. Various rhamnolipid components and relatedsurfactant compositions are available from Jeneil Biosurfactant Co.,LLC, under the Zonix trademark.

Example 25

For instance, illustrating such rhamnolipid-related variations, a rangeof compositions can be prepared with one or more rhamnolipid componentsand one or more FFC compositions of this invention (and/or one or moreFFC components thereof), for use as or in conjunction with apost-harvest wash or treatment of a wide range of fruits and vegetables.Without limitation, in such a composition, a rhamnolipid component,(e.g., as described in the aforementioned '572 application) can bepresent in an amount ranging from about 0.1 wt. % to about 99.9 wt. %,and an FFC composition/component (e.g., compositions of Tables 2-7 and10, above) can be present in an amount ranging from about 99.9 wt. % toabout 0.1 wt. %. With reference to applicable EPA regulations, there isno tolerance limit for the aforementioned Zonix rhamnolipid surfactants.Likewise, there is no tolerance limit for the FFCcompositions/components of this invention. Accordingly, food treatedwith such rhamnolipid/FFC compositions can be consumed without furtherwashing.

Example 25a

In accordance with the foregoing, a rhamnolipid/FFC composition can beused to wash citrus fruits. One such wash/bath composition was preparedusing an 8.5% rhamnolipid solution (in water) and a 5% FFC solution(e.g., the composition of Table 10 in water). One gallon of a 95:5 (v/v)mixture was diluted to 425 gallons. Using procedural protocols known inthe industry or otherwise required under applicable state or federalregulations, the composition was used effectively to clean and penetratecitrus peel—killing both surface and interior bacteria and fungi. Whileeffective results were demonstrated with citrus fruit, this and relatedrhamnolipid/FFC compositions can be used comparably in conjunction withpost-harvest wash or treatment of any fruit or vegetable (e.g., withoutlimitation, blueberries, tomatoes, grapes, onions, sugar beets, sweetpotatoes, apples, pears, pineapples and various other tropical producesuch as but not limited to noni and acai fruit, etc.). Fruits/vegetableswashed or treated with FFC compositions of this example would berecognized as safe and hygienic for human consumption.

Example 25b

Whether or not having an incorporated rhamnolipid component, various FFCcompositions of this invention can be used to treat various fruits andvegetables (e.g., without limitation, pears, peaches, apples, tomatoes,apricots, mangos and the like) before or upon packaging or canning toreduce bacterial/fungal loads.

Example 26

Sourcing of FFC Component Compounds. Component compounds for use incompositions of this invention can be obtained commercially or preparedusing synthetic techniques of the sort well-known or otherwise describedin the literature. (See, e.g., U.S. Pat. No. 6,911,338, the entirety ofwhich is incorporated herein by reference.)

Alternatively, as can be preferred in conjunction with certainembodiments—including but not limited to animal and human food andbeverage items, personal care and cosmetic products and relatedprocessing and manufacturing techniques, GRAS component compounds andrelated FFC compositions of this invention can be derived naturallythrough fermentation techniques, and are available under the Flavorzontrademark from Jeneil Biosurfactant Co., LLC of Saukville, Wis.Accordingly, various compositions of this invention, depending onend-use or application, can comprise compounds derived from bacterialfermentation, compounds chemically synthesized and various mixtures ofcompounds of fermentative and synthetic origin.

With reference to the preceding, the following examples illustratenon-limiting use or incorporation of one or more compositions of thisinvention, such use or incorporation as would be understood by thoseskilled in the art made aware of this invention, and described in thecontext of several prior patents, each of which is incorporated hereinby reference for purpose of demonstrating that one skilled in the artwould understand such use or incorporation of this invention.

Example 27

Illustrating other embodiments, various compositions of this inventioncan be formulated for use as an additive for a fruit drink, such asdescribed in the incorporated U.S. Pat. No. 6,566,349. For instance,compositions of this invention may be added to a juice in combinationwith or as a substitute for a flavonoid compound and/or an antioxidant,or may be pre-applied to fruits and vegetables before processing, toincrease product shelf life. As would be understood by those skilled inthe art, such compositions of the '349 Patent can be modified to includeone or more compositions of the present invention in an amount of whichfor any end-use application can be determined, in a straight-forwardmanner without undue experimentation.

Example 28

Compositions of the present invention can also be formulated for use inpreserving tea and tea/fruit mixture beverages, such as described in theincorporated U.S. Pat. No. 5,866,182. For instance, compositions of thepresent invention may be used in combination with or as a replacementfor K-sorbate and/ Na-benzoate, ascorbic acid, and dimethyl dicarbonate.As will be understood by those skilled in the art, such beverages of the'182 Patent (e.g., example 1 thereof) may be modified to include one ormore compositions of the present invention, an amount of which for anyparticular application may be determined in a straight-forward mannerwithout undue experimentation.

Example 29

Compositions of the present invention can also be formulated for use inpreserving and/or enhancing the antimicrobial effect of antiperspirantsand deodorants, such as described in the incorporated U.S. Pat. No.5,176,903. For instance, compositions of the present invention can beused in combination with or as a replacement for parabens,imidazolidinyl urea, quaternium-15, benzyl alcohol, phenoxyethanol, andvarious other suitable preservatives (e.g., as described in examples 1-3thereof) and added to such antiperspirant/deodorant to protect againstdegradation, extend shelf life and/or enhance effectiveness, one or moresuch compositions in an amount of which can be determined in astraight-forward manner without undue experimentation by one havingordinary skill in the art.

Example 30

Compositions of the present invention can also be formulated for use inantiperspirants, such as described in the incorporated U.S. Pat. No.4,548,808. For instance, one or more compositions of the presentinvention can be added to the substantially anhydrous non-alcoholicantiperspirant products described in the '808 Patent (e.g., examples 1-6thereof) in effective amounts readily determined without undueexperimentation by one having ordinary skill in the art—to extendshelf-life and enhance antimicrobial effect.

Example 31

Compositions of the present invention can also be formulated for use inanimal/pet food, for example dog food, such as described in theincorporated U.S. Pat. No. 3,119,691. One having ordinary skill in theart would recognize that one or more of the present compositions can beadded to low hydration dog food, high moisture dog food, andrehydratable dog food to (e.g., to the product formulations describedtherein) prolong the shelf-life of products disclosed in the '691Patent, such composition(s) in an amount readily determined withoutundue experimentation.

Example 32

Compositions of the present invention can also be formulated for use incat litter, such as described in the incorporated U.S. Pat. Nos.5,060,598 and 4,721,059. Various absorbent materials, including, forexample, clay, alfalfa, wood chips, and saw dust, and increasedabsorbent materials including clay-like filler ('059 Patent) and peat('598 Patent) are used to absorb urine and control odor. One or morecompositions of the present invention may be used in conjunction withthese materials (e.g., sprayed on or otherwise incorporated into) toreduce or eliminate microbial activity and control odor after use of thelitters, such composition(s) in an amount readily determined withoutundue experimentation.

Example 33

Compositions of the present invention can also be formulated for use inspray disinfectant applications, such as described in the incorporatedU.S. Pat. No. 6,250,511. The '511 Patent describes including a treatmentsolution in the spray bottle comprising between about 25% and 75% of atleast one glycol compound, between 0.2% and 60% of an antimicrobialcomponent, between about 5% and 45% of a surfactant, and optionallyeffective amounts of fragrances, dyes and other additives (at col. 3thereof). For instance, one or more compositions of the presentinvention can be used in conjunction with a disinfectant of the '511Patent as a replacement for the antimicrobial component, or as anadditive thereto, such composition(s) in an amount readily determined byone skilled in the art without undue experimentation.

Example 34

Compositions of the present invention can also be formulated forcleaning and/or disinfecting food and beverage processing equipment,such as described in the incorporated U.S. Pat. No. RE 40,050. While the'050 Reissue teaches a halogen dioxide composition, such a formulationcould be modified by one skilled in the art to substitute one or morecompositions of the present invention, such composition(s) in an amountreadily determined without undue experimentation and contacted with orapplied to such processing equipment using apparatus and techniques ofthe sort described in the '050 Reissue (e.g., as described in cols. 3-4thereof).

Example 35

Compositions of the present invention can also be formulated for use inpreserving wood, such as described in the incorporated U.S. Pat. No.4,988,576 (and for lignocellulosic-based composites described inincorporated U.S. Pat. No. 7,449,130). The '576 Patent teachesimpregnating wood with a solution of a preservative compositioncomprising a graft copolymer of lignosulfonate, hydroxyl benzyl alcoholand a metal salt or a mixture of metal salts, or alternately of at leastone metal salt of a graft copolymer of lignosulfonate, the copolymerbeing a reaction product of lignosulfonate and acrylic monomers. Forinstance, one or more compositions of the present invention may be usedalone or in combination with such preservatives taught by the '576Patent (or the '130 Patent), as described, respectively, in examples 1-4and 1-2 thereof, to impregnate and preserve wood, such composition(s) inan amount readily determined by one having ordinary skill in the artwithout undue experimentation.

Example 36

Compositions of the present invention can also be formulated for usewith sanitizing and/or disinfecting wipes, such as described in theincorporated U.S. Pat. No. 4,575,891, which teaches a pad partiallysaturated with a disinfectant (e.g., col. 2 thereof). The '891 Patentdescribes suitable disinfectants as alcoholic solutions, and otherantiseptic solutions. For instance, one or more compositions of thepresent invention may be used alone or in combination with suchdisinfectants and incorporated into such a wipe material, suchcomposition(s) in an amount readily determined and incorporated by oneskilled in the art without undue experimentation.

Example 37

Compositions of the present invention can also be formulated for usewith a hand sanitizing lotion, such as described in the incorporatedU.S. Pat. No. 6,187,327. For instance, one or more compositions of thepresent invention can be formulated to be added to and work inconjunction with the lotion of the '327 Patent or to replace any of theactive ingredients of the lotion to improve antimicrobial effect. The'327 Patent also discloses various other known hand sanitizers (e.g. anamphoteric-cationic surfactant, a cationic surfactant, a wetting agent,and a nonionic regressing agent). Regardless, a composition of thepresent invention can be incorporated as a replacement for or use inconjunction with any of the active ingredients in any such handsanitizer, such composition(s) in an amount readily determined withoutundue experimentation.

Example 38

Compositions of the present invention can also be formulated for use intreating edible or crop seeds, such as described in the incorporatedU.S. Pat. No. 4,581,238, which teaches contacting with seeds with steamhaving a sorbate dispersed therein (e.g., in cols. 2-5 thereof). Forinstance, using techniques and apparatus disclosed therein, one or morecompositions of the present invention can be volatilized or otherwiseapplied to such seeds, such composition(s) in an amount readilydetermined by one having ordinary skill in the art without undueexperimentation.

Example 39

Compositions of the present invention can also be formulated for use inpreventing or inhibiting the growth of spoilage organisms, such asdescribed in the incorporated U.S. Pat. No. 4,356,204, which teachescontacting food with an effective growth inhibiting amount of aketohexanoic acid (e.g., in cols. 2-3 thereof). One or more compositionsof the present invention can be used alone or with such a ketohexanoicacid to further inhibit and/or kill spoilage organisms. Likewise,incorporated U.S. Pat. No. 2,711,976 suggests the use of amino acids toincrease the resistance of custard foods to spoilage organisms andStaphylococcus species. Again, one or more compositions of the presentinvention may be used alone or in combination with or as a substitutefor such amino acids. Likewise, incorporated U.S. Pat. No. 2,866,819suggests the use of sorbic acid as a preservative in foods. Again, oneor more compositions of the present invention may be used alone or incombination or as a substitute for sorbic acid. Likewise, incorporatedU.S. Pat. No. 2,910,368 discloses the use of EDTA with sorbic acid toincrease the shelf life of vegetables. Again, one or more compositionsof the present invention may be used alone or in combination with EDTAand/or sorbic acid. In each instance, such composition(s) of the presentinvention can be used in an amount readily determined by one skilled inthe art without undue experimentation.

Example 40

Compositions of the present invention can also be formulated for use intreating fruit, seeds, grains, and legumes, such as described in theincorporated U.S. Pat. No. 5,273,769, which teaches placing any of theitems to be treated in a container then introducing carbon dioxide andammonia. For instance, using apparatus and techniques described therein(e.g., examples 1-4), one or more compositions of the present inventionmay be utilized effectively as would be understood in the art withoutundue experimentation.

Example 41

Compositions of the present invention may also be formulated for use intreating dental and medical articles/devices and implants, the latter asmore specifically described in the incorporated U.S. Pat. No. 6,812,217,which teaches an antimicrobial polymer film applied to the exteriorsurface of an implantable medical device. For instance, using techniquesof the sort described therein, one ore more compositions of the presentinvention may also be deposited on or otherwise incorporated with such adevice or article (whether medical or dental) or polymer film thereon(e.g., as described in cols. 5-6) to provide antimicrobial effect, suchcomposition(s) in an amount readily determined by one of ordinary skillin the art without undue experimentation.

Example 42

Compositions of the present invention may also be formulated for use intreatment of textiles, such as in the incorporated U.S. Pat. No.5,968,207, which teaches application of triclosan ester to textilefibers or fabric by diffusion or impregnation. For instance, one or morecompositions of the present invention may be formulated for use alone orin combination with such compound to improve anti-microbial propertiesof a textile or fibers thereof, whether a man-made, natural, or a blend(e.g., as described in cols. 2-3 of the '207 Patent), suchcomposition(s) in an amount readily determined by one of ordinary skillin the art without undue experimentation.

Example 43

Compositions of the present invention can be formulated for treatment ofsurfaces of a food processing facility, related equipment andfoodstuffs, such as described in the incorporated U.S. Pat. No.7,575,744. For instance, using techniques and apparatus of the sortdescribed therein, one or more compositions of the present invention maybe formulated and disposed on equipment and foodstuff surfaces in a widerange of food processing facilities to reduce or eliminate microbialactivity, such facilities/equipment including but not limited to snack,poultry, citrus, peanut and related food processing facilities/equipment(see, e.g., col. 20). Such composition(s) can be employed in an amountreadily determined by one skilled in the art without undueexperimentation.

Example 44

Compositions of the present invention can also be formulated for use inthe treatment of microbial-related diseases (i.e., mastitis, hoof &mouth, etc.) in farm animals and livestock, and to inhibit microbialgrowth on crops, plants, grains, and other foodstuffs, such as describedin the incorporated U.S. Pat. No. 7,192,575, which teaches applicationof and a composition comprising clove bud oil, eucalyptus oil, lavenderoil, tea tree and orange oil. For instance, one or more compositions ofthe present invention can be formulated for use alone or in combinationwith that of the '575 Patent (e.g., examples 1-2 thereof), suchcomposition(s) in an amount readily determined by one of ordinary skillin the art without undue experimentation.

Example 45

Compositions of the present invention can also be formulated for use inpreserving foodstuffs such as dressings, sauces, marinades, condiments,spreads, butters, margarine, dairy based foods, and the like frommicrobial spoilage, such as described in the incorporated U.S. Pat. No.6,156,362, which teaches a combination of antimicrobial components. Oneor more compositions of the present invention can be formulated for usealone or in combination with one or more of the components of the '362Patent (e.g., examples 1-4 thereof), such composition(s) or in an amountreadily determined by one of ordinary skill in the art without undueexperimentation.

Example 46

Compositions of the present invention can be formulated forincorporation with a wide range of water-based and organic-based paints,stains and related surface coatings, such as described in theincorporated U.S. Pat. No. 7,659,326 and the authorities recited therein(e.g., Kirk-Othmer-Paint; pp. 1046-1049, Vol. 17; 1996, by Arthur A.Leman, the disclosure of which is also incorporated herein by referencein its entirety). For instance, one or more compositions of the presentinvention may be formulated for use or alone in combination with anotherantimicrobial component described in the detailed description andexamples 1 and 3 of the '326 Patent, such composition(s) in an amountreadily determined by one skilled in the art without undueexperimentation.

Example 47

Compositions of the present invention can also be formulated for use orincorporation into after-shave products, such as those described in theincorporated U.S. Pat. No. 6,231,845. For instance, one or morecompositions of the present invention can be used in conjunction withcomponents of the sort described in examples 1-6 of the '845 Patent, toprovide antimicrobial effect to such after-shave products of the priorart. Such compositions can be present in an amount readily determined byone skilled in the art without undue experimentation.

Example 48

Compositions of the present invention can also be formulated for use orincorporation into a product for treatment of a carcass, meat or meatproduct (e.g., of mammals, birds, fishes, clams, crustaceans and/orother forms of seafood, and other edible species), such as described inthe incorporated U.S. Pat. No. 7,507,429. For instance, one or morecompositions of the present invention may be formulated for use alone orin combination with another antimicrobial component, for incorporationinto a product of the sort described in the '429 patent. Suchcomposition(s) can be present in an amount readily determined by oneskilled in the art without undue experimentation, and the correspondingproduct(s) can be applied or otherwise utilized with techniques andapparatus described in the '429 patent or as would otherwise beunderstood by those skilled in the art made aware of this invention.(See, e.g., the meat processing, spraying, immersing and treating, andcomposition and component sections of the detailed description of the'429 Patent.)

Example 49

Compositions of the present invention can also be formulated for use orincorporation into a material (e.g., a material for a coating or otherincorporation) for a food product, such products including but notlimited to snack foods, cereal foods and other food components, suchsnack and cereal foods and materials of the sort described in theincorporated U.S. Pat. No. 7,163,708. Without limitation as to how suchmaterials can be applied, one or more compositions of the presentinvention can be used alone or in conjunction with one or more of theantimicrobial or preservative components of such materials, as describedin the detailed description of food products and coating materials, ofthe '708 patent. Accordingly, as would be understood by one skilled inthe art, such a composition can be present in an amount readilydetermined without undue experimentation.

Example 50

Compositions of the present invention can be formulated forincorporation with a variety of edible spread compositions, includingbut not limited to peanut butter compositions, such as those describedin the incorporated U.S. patent number 7,498,050. For instance, as wouldbe understood by one skilled in the art, one or more compositions of thepresent invention can be used in conjunction with such edible spreadproducts to provide or otherwise enhance antimicrobial effect, asdescribed in examples 1-2 of the '050 Patent, such composition(s) as canbe present in an amount readily determined without undueexperimentation.

Example 51

Compositions of the present invention can be formulated forincorporation with a wide range of pest control compositions, such asthose described in the incorporated U.S. Pat. No. 6,720,450 (e.g., insections 2-3 of the detailed description thereof). For instance, one ormore compositions of the present invention may be formulated for usealone or in combination with another antipesticidal component, such asthat described in the '450 patent. Likewise, one or more compositions ofthis invention can be formulated as described therein, with a suitablecarrier component, for use against various blood-imbibing insects,including but not limited to various types of mosquitoes, and insectpests of agricultural crops. The present compositions can be used asdescribed therein for direct contact, inhibition and/or elimination ofmosquitoes, including the larvae, pupa and/or adult forms thereof.Alternatively, the present compositions can be used and/or formulatedfor repellent action. Regardless, such composition(s) can be present inan amount readily determined by one skilled in the art without undueexperimentation and can optionally include a surfactant component. Sucha surfactant can be a biosurfactant. Without limitation, such abiosurfactant can be selected from monorhamnolipids, dirhamnolipids andcombinations thereof.

With reference to paragraphs [0046]-[0047], [0051]-[0052] and [0105] andalternate compositions of the sort described in and available throughuse of the FFCs of Tables 2-7 and 10, the following examples demonstratethe use of several such FFC compositions and related articles, inaccordance with this invention.

Example 52

Several assays were undertaken using representative antimicrobialcompositions against various test organisms. Plugs of inoculum (3×3 mm)were streaked at a minimal level, then exposed, respectively, to vaporsfrom compositions B-L placed in a microcup center well. Radial growthfrom each plug was measured (mm) after 38 hours at room temperature.

TABLE 14 Test column Pythium Rhizoc Vert Asp Phyto Fus Botr Scl BacillusE. coli A 31 8 2.5 3.5 3.0 9.5 5.5 7 growth growth B 0 0 0 1 0 0.2 0.51.7 slight 0 C 0 0 0 0.5 0 0.7 0.2 0.8 trace 0 D 0 0 0 0.45 0 0.7 0 0 00 E 0 0 0 0.4 0 0.5 0.1 0.7 0 0 F 0 0 0 0.1 0.1 0 0.1 0.7 trace 0 G 0 00 0.2 0.1 0.1 0.1 3.5 0 0 H 0 0 0 0.1 0.15 2.5 0.2 0.15 0 0 I 0 0 0 0.150 0.3 0.1 0.15 0 0 J 0 0 0 0.7 0 0.1 0 0 0 0 K 0 0 0 0.7 0 0.3 0.15 1.70 0 L 0 0 0 0.07 0 1.5 0 0.8 0 0 Antimicrobial compositions tested: A =control (no treatment) B = a composition of Table 10, above; 10microliters C = propanoic acid:isoamyl acetate, 7:2 (v/v); 9 microlitersD = propanoic acid:isobutyl isobutyrate, 7:2 (v/v); 9 microliters E =propanoic acid:isopentyl isobutyrate, 7:2 (v/v); 9 microliters F =propanoic acid:allyl acetate, 7:2 (v/v); 9 microliters G = propanoicacid:methyl isobutyrate, 7:2 (v/v); 9 microliters H = propanoicacid:phenylethyl acetate, 7:2 (v/v); 9 microliters I = propanoicacid:benzaldehyde, 7:2 (v/v); 9 microliters J = propanoic acid:isoamylacetate:benzaldehyde, 7:2:2 (v/v/v); 11 microliters K = propanoicacid:all esters above in equal mix, 7:2 (v/v); 9 microliters L =propanoic acid:all esters above in equal mix:benzaldehyde, 7:2:2(v/v/v); 11 microliters.

Test Organisms: Pythium ultimum (Pythium); Rhizoctonia solani (Rhizoc);Verticullum dahliae (Vert); Aspergillus fumigatus (Asp); Phytophthoracinnamomi (Phyto); Fusarium solani (Fus); Botrytis cinerea (Botr);Sclerotinia sclerotiorum (Scl); Bacillus subtilus (Bacillus); andEscherichia coli (E. coli).

As demonstrated above, specific compositions of this invention can bedesigned for differential antimicrobial effect. For instance, whilecomposition B was somewhat less than advantageous against the Botrytisand Sclerotinia species, composition D inhibited growth completely,under the assay conditions employed. Regardless, an antimicrobialcomposition of this invention—whether used neat, in vapor form orincorporated with a carrier component—can show beneficial results with apropanoic acid component present at a ratio of at least about 7:about 1with respect to any other composition component. (See FIG. 10 forstructures and nomenclature of FFCs employed in compositions B-L.) Withrespect to compositions B-L, it will be understood by those skilled inthe art that while certain acid esters are specifically referenced,various other C₂-about C₅ acid esters and combinations thereof can beused with comparable effect.

Example 53

In accordance with and illustrating use of various articles of thisinvention, granules of bentonite clay (e.g., from Al Harvey of Lovell,Wyo.) were impregnated with a representative composition of Table 10,above, (˜0.80 ml/g of bentonite) and placed in an open-top enclosure.Granules of this article and part of a bunch of raspberries (i.e., apost-harvest perishable food item) were placed in a sealed container.After seven days, little mold or other microbial growth was evident.(See, FIG. 11A.) By comparison, using a control system of bentonitegranules without incorporated antimicrobial composition, raspberriesfrom the same bunch were stored in a sealed container over the same timeperiod: excessive spoilage was observed. (See, FIG. 11B.)

Example 54

Various other compositions of this invention, including withoutlimitation compositions B-L of Example 52, can be incorporated with asolid carrier component. For instance, commercially-available bentoniteclay granules can be impregnated with such a composition, for use inconjunction with a vapor-permeable enclosure, such as a sealed orre-sealable flexible bag or pouch. Whether a suitably-dimensioned meshor of a porous non-woven Tyvek® or functionally-similar material, such abag/pouch can provide an article with all components (i.e., anantimicrobial composition, a carrier and an enclosure) meeting FDAspecifications relating to food processing and contact.

Example 55

With reference to paragraphs [0055] and [0119] and Example 11, above,bentonite clay granules can be impregnated with a composition of Table10, then packaged into a vapor permeable pouch, or similar suchenclosure, and positioned proximate to a deposit or collection of humanwaste or refuse. Without limitation, such an article can be placed in oradjacent to a container of human waste—optionally, as a preliminarymeasure en route to a final treatment and/or disposal.

Example 55a

With reference to paragraphs [0057]-[0062] and [0119], an antimicrobialcomposition useful in conjunction with the end-use application ofexample 55 is represented, below.

Acetaldehyde Ethyl Acetate Propanoic acid, 2-methyl-, methyl esterEthanol Acetic acid, 2-methylpropyl ester Propanoic acid, 2-methyl-,2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol, 3-methyl-, acetatePropanoic acid, 2-methyl-, 2-methylbutyl ester Acetic acid,2-phenylethyl ester

Example 55b

Again, with reference to paragraphs [0057]-[0062] and [0119], anotherantimicrobial composition useful in conjunction with the end-useapplication of example 55 is represented, below.

Acetaldehyde Ethyl Acetate Propanoic acid, 2-methyl-, methyl esterAcetic acid, 2-methylpropyl ester Propanoic acid, 2-methyl-,2-methylpropyl ester 1-Propanol, 2-methyl- 1-Butanol, 3-methyl-, acetatePropanoic acid, 2-methyl-, 2-methylbutyl ester Acetic acid,2-phenylethyl ester

Example 55c

Further, with reference to paragraphs [0057]-[0062] and [0119], anotherantimicrobial composition useful in conjunction with the end-useapplication of example 55 is represented, below.

Ethyl Acetate Propanoic acid, 2-methyl-, methyl ester Acetic acid,2-methylpropyl ester Propanoic acid, 2-methyl-, 2-methylpropyl ester1-Propanol, 2-methyl- 1-Butanol, 3-methyl-, acetate Propanoic acid,2-methyl-, 2-methylbutyl ester Acetic acid, 2-phenylethyl ester

Example 56

With further reference to paragraphs [0077] and [0087]-[0091], Tables2-7 and 10 and Examples 32-33, various FFC compositions of thisinvention can be used to prepare cat litter and related animal careproducts. For instance, bentonite clay granules or other solid carriercomponents are contacted or impregnated with an antimicrobialcomposition (e.g., 0.20 wt. % to about 10.0 wt. % or, in certainembodiments, about 1.0 wt. % to about 3.0 wt. %) of the sort representedbelow.

wt. % Compound about 0.1-about 10 Acetaldehyde about 0.5-about 10 EthylAcetate about 0.1-about 10 2-Butanone about 4-about 20 Propanoic acid,2-methyl-, methyl ester about 1.5-about 15 Ethanol about 0.1-about 10Acetic acid, 2-methylpropyl ester about 20-about 40 Propanoic acid,2-methyl-, 2-methylpropyl ester about 0.1-about 10 1-Propanol, 2-methyl-about 20-about 40 1-Butanol, 3-methyl-, acetate about 1.0-about 30Propanoic acid, 2-methyl-, 2-methylbutyl ester about 2-about 101-Butanol, 3-methyl- about 40-about 80 Propanoic acid, 2-methyl- about0.1-about 10 Acetic acid, 2-phenylethyl esterAlternatively, compositions of the sort described in Examples 52(compositions B-L) and Examples 55a-55c can also be used in thepreparation of such a litter article. Regardless, the relative amount ofany such component can be adjusted for any particular formulation,desired antimicrobial effect and/or to accommodate the presence of anyone or more additives of the sort described herein including but notlimited to perfuming/fragrance agents.

Example 57

With reference to paragraphs [0026] and [0087] and Example 52, above,compositions of this invention can be prepared using propanoic acid inconjunction with one or more acid salts, including but not limited tosalts of any one or more C₂-about C₆ acids. Such acid salts, includingthose of food grade quality, can be prepared, as described below, andare available from sources well-known to those skilled in the art,including but not limited to Sigma-Aldrich (St. Louis, Mo.).

Example 57a

In accordance with certain embodiments of this invention and withreference to paragraph [0061], the following compositions can beconsidered without limitation as to component amount or concentration,such compositions including:

A. propanoic acid:a C₄ acid salt:

B. propanoic acid:a C₅ acid salt;

C. propanoic acid:a C₆ acid salt;

D. propanoic acid:a combination of C₄ acid salts;

E. propanoic acid:a combination of C₅ acid salts;

F. propanoic acid:a combination of C₆ acid salts; and

G. propanoic acid:a combination of C₄-C₆ acid salts.

Such C₄-C₆ acid salts and combinations thereof can be, withoutlimitation, selected from salts of n-C₄-n-C₆ monocarboxylic acids andstructural isomers thereof and suitable corresponding C₄-C₆polycarboxylic and hydroxypolycarboxylic acids including but not limitedto salts of 2-methylpropanoic acid, 2-methylbutanoic acid,3-methylbutanoic acid, 2,3-dimethylpropanoic acid, 2,2-dimethylpropanoicacid, tartaric acid, citric acid and other C₄-C₆ mono- and(hydroxy)polycarboxylic acids, as would be understood by those skilledin the art made aware of this invention, such salts as can be, withoutlimitation, selected from alkali (e.g., sodium, potassium, etc.),alkaline-earth (e.g., calcium, magnesium, etc.) and quaternary amine(e.g., ammonium, etc.) salts of such acids. Such compositions can beprepared by mixing the components neat or with a suitable solvent ordiluent such as but not limited to water and/or an aqueous alcohol and,optionally, in the presence of a surface active component such as arhamnolipid.

Example 57b

With reference to any composition of Example 57a, various othercompositions of this invention can include one or more esters of one ormore C₂-about C₅ acids and structural isomers thereof, in addition to oras a substitute for any such acid salt component.

Example 57c

With reference to any composition of Examples 57a-b, various othercompositions of this invention can include one or more C₂-about C₈aldehyde components in addition to or as a substitute for any such acidsalt and/or acid ester component.

Example 57d

With reference to the compositions of Examples 57a-c, various othercompositions of this invention can include another C₂-about C₆ acidcomponent. Without limitation, such an additional acid component can beselected from acetic acid, isobutyric acid, citric acid and combinationsthereof, in addition to or as a partial substitute for propanoic acid.

Example 57e

Notwithstanding the compositions of Examples 57 and 57a-d, compositionsof propanoic acid and at least one C₄-about C₆ acid salt, compositionsof propanoic acid and at least one additional C₂-about C₆ acid componentand compositions of propanoic acid and at least one C₄-about C₆ acidsalt providing the absence of an acid ester, aldehyde and/or ketone canbe utilized. Regardless, as discussed above, any composition of thisinvention can be absent naphthalene and azulene derivative compounds andother fused aromatic compounds and hydro derivatives thereof.

Example 58

With reference to any one or more preceding compositions of Examples 57and 57a-e, such composition(s) can be incorporated into an article ofmanufacture, including but not limited to those of the sort discussedherein or otherwise used as described above. Generally, withoutlimitation and as described above, one or more such compositions can beincorporated into a food ingredient or nutraceutical (e.g., Example17d), a range of food products (e.g., at paragraphs [0032], [0052] and[0066]) including processed foods such as peanut butter, humus, andvarious dips and spreads (e.g., Example 18), cheeses (e.g., at paragraph[0067]) and other dairy and related products, solid carrier components(e.g., Examples 53-56), and such carrier components in conjunction withvapor permeable enclosures (e.g., Examples 53-55) and as a substitutefor sorbic acid, benzoic acid and sorbate and benzoate salts (e.g.,Examples 28 and 39).

Example 59

With reference to Examples 57 and 57a-e, comparative testing of arepresentative composition of propanoic acid and a salt of isobutyricacid (e.g., potassium) demonstrated this invention as providingantimicrobial effect when incorporated into a food item. Morespecifically, 0.1 gram of potassium isobutyrate was added to 20microliters of propanoic acid. (Similarly, several referencecompositions were also prepared, as indicated in Table 15, below.) Thetest and reference compositions were hand-mixed into 10 grams of freshrefrigerated humus (Costco) and placed in a sealed container. Thetreated and control containers were held at 25° C. then examined andsampled at 10 and 18 days. Sampling of each container was accomplishedwith a sterile transfer needle, with approximately 1 mg. streaked onto apotato dextrose agar (PDA) Petri plate, incubated for 30 hours, thenexamined. Results are summarized in Table 15, below.

TABLE 15 Appearance Taste Appearance Taste Treatment (10 days) (10 days)(18 days) (18 days) Control Odiferous product; Not taste tested Advancedfungal Totally 10 g humus fungal growth growth over repugnant visible;almost the entire smell; not taste considerable surface of the foodtested growth on PDA product A Product appeared Excellent taste, Theproduct Taste remains normal, as per as per original appeared normal,comparable to original humus; no humus as per original that of originaldiscernable humus; no refrigerated microbial growth microbial growthhumus product on PDA plate on product surface; no discernable microbialgrowth on PDA plate B Product appears Acidic taste Fungal coloniesUnacceptable about the same as and tangy developed on tangy acid-likeoriginal humus; flavor product surface taste light microbial growthpattern on PDA plate C Product appeared Acid-like taste No apparentfungal Stronger normal as per or other bacterial acid-like tasteoriginal humus; growth on product considerable surface microbial growthon PDA plate D Odiferous; great Putrid taste Some microbial Putrid tastedeal of microbial growth on surface growth on PDA of product plate A:0.1 g K isobutyrate in 20 μl propanoic acid, in 10 g humus B: 20 μlpropanoic acid, in 10 g humus C: 0.2 g Na₂HPO₄ in 100 μl propanoic acid,in 10 g humus D: 0.1 g K isobutyrate, in 10 g humus

Example 60a

Purpose: Determine if a composition of this invention will inhibit moldin an enzyme modified cheese (EMC) cheddar product (EMC CH) which issusceptible to mold growth due to its high pH and low titratable acidity(TA). Procedure: Prepare a composition, obtain an EMC cheddar product,and prepare a Blue Cheese Slurry as a source of mold spores to deliver1-10 CFU/100 gram sample. Test efficacy of the composition.

Preparation of Antimicrobial Composition:

-   -   1. Prepare a 4 M (Molar) solution of Potassium Isobutyrate        (K-IB) by adding 394.92 g Isobutyric Acid and 498.76 g of 45%        KOH (Potassium Hydroxide) to a 1-L volumetric flask.    -   2. Add deioinized water to bring volume up to 1 L.    -   3. Temper to room temperature and readjust volume.    -   4. Measure pH=8.11    -   5. Weigh all ingredients in the percentages in the table below,        including: 4 M Potassium Isobutyrate, propionic acid, acetic        acid, and citric acid to prepare the final composition.

-   The composition of this example (designated FF#2) is comprised of    potassium isobutyrate, propionic acid, acetic acid and citric acid.

-   It has a pH of 5.39.

Ingredient % grams K-IBA (4M) 67.0 16.75 Propionic Acid 20.0 5.00 AceticAcid 10.0 2.50 Citric Acid 3.0 0.75 100.0 25.00

Enzyme Modified Cheese Cheddar Product (EMC CH) [Production Lot#140210]:

EMC Specifications CH Target % Moisture 43.5 42-46 % Fat 28.0 26-30 TA(Titratable acidity) 18.5 20-24 % Salt 2.1 1-2 pH 5.9 5.2-6.0 Mold Count(cfu/g) <10 <10 GC/LC assay (mg/g) Isobutyric Acid 2.112 Propionic Acid0.024 Acetic Acid 2.307

Preparation of Blue Cheese Slurry (BM) (Blue Mold)

-   -   1. Previous plating yielded 3.4 billion CFU/g of Penicillium        roqueforti in the blue cheese.    -   2. Add 1 g Blue Cheese into 9 ml Sodium Citrate (2.0%) buffer        (1/10 dilution).    -   3. Make one dilution (1/10) and 3 serial dilutions of 0.1 ml        into 9.9 ml Sodium Citrate buffer.    -   4. Plate 0.2 ml on each sample and control “C” and “D”.    -   5. BM calculation to equate 6.8 CFU/sample.

Experiment:

-   -   1. Place 100 g of EMC CH as Negative Control “Aa” in white cups        and “Ab” in sterile cups.    -   2. Place 99 g of EMC CH as Negative Control “B” with 1 ml FF#2        (1.0%) in white cup.    -   3. Place 100 g of EMC CH with 0.2 ml BM on the top surface as        Positive Control “C” in white cup.    -   4. Place 100 g of EMC CH with 0.2 ml BM mixed within as Positive        Control “D” in white cup.    -   5. Test white cups “E” will have 1 ml FF#2 (1.0%) in 99 g EMC CH        with 0.2 ml BM inoculated on the top surface.    -   6. Test white cups “F” will have 1 ml FF#2 (1.0%) in 99 g EMC CH        with 0.2 ml BM inoculated within product.    -   7. Number and label white test cups.    -   8. Incubate at 25° C. for 12 weeks (84 days).    -   9. Sample one test cup for initial pH, TA and mold count.    -   10. Test mold counts using PDA (Potato Dextrose Agar w/        1%Tartaric Acid) on weeks 2, 4, 8, and 12.    -   11. Sample final pH and TA at 12 weeks.    -   12. Record Results.    -   13. Obtain a GC/MS assay of Sample A and B to compare FF#2        chemical effects in product.

EMC CH EMC CH EMC CH + EMC CH EMC CH EMC CH 1% FF2 1% FF2 Control 1%FF#2 BM top BM mix BM top BM mix Sample Test “A” “B” “C” “D” “E” “F”Week 1, Day 7 Aa/Ab-1 B1 C1 D1 E1 F1 Week 2, Day 14 Aa/Ab-2 B2 C2 D2 E2F2 Week 4, Day 28 Aa/Ab-3 B3 C3 D3 E3 F3 Week 8, Day 56 Aa/Ab-4 B4 C4 D4E4 F4 Week 12, Day 84 Aa/Ab-5 B5 C5 D5 E5 F5

Results:

Visible Mold Mold Count Test Cup pH TA (Yes/No) cfu/g Aa1-initial 6.0819.68 no <10 Aa1-day 7 no na Aa2-day 14 yes Aa3-day 28 yes Aa4-day 56Aa5-day 84 Ab1-initial 5.96 19.81 no <10 Ab1-day 7 no NA Ab2-day 14 noAb3-day 28 yes Ab4-day 56 Ab5-day 84 B1-initial 5.71 23.7 no <10 B1-day7 no NA B2-day 14 no B3-day 28 no B4-day 56 B5-day 84 C1-initial 6.0320.88 no 6.8 C1-day 7 no NA C2-day 14 no C3-day 28 no C4-day 56 C5-day84 D1-initial 5.92 20.61 no 6.8 D1-day 7 no NA D2-day 14 no D3-day 28 noD4-day 56 D5-day 84 E1-initial 5.63 20.3 no 6.8 E1-day 7 no NA E2-day 14no E3-day 28 no E4-day 56 E5-day 84 F1-initial 5.53 19.1 no 6.8 F1-day 7no NA F2-day 14 no F3-day 28 no F4-day 56 F5-day 84

Example 60b

Purpose: Determine if FF#2 will inhibit mold in a Lipolyzed creamproduct (LC) which is susceptible to mold growth due to its high pH andlow TA. Procedure: Prepare FF#2, obtain Lipolyzed cream product withoutpotassium sorbate, and prepare a Blue Cheese Slurry as a source of moldspores to deliver 1-10 CFU/100 gram sample. Test efficacy of FF#2.

Preparation of FF#2:

-   -   1. Prepare a 4 M (Molar) solution of Potassium Isobutyrate        (K-IB) by adding 394.92 g Isobutyric Acid and 498.76 g of 45%        KOH (Potassium Hydroxide) to a 1-L volumetric flask.    -   2. Add deioinized water to bring volume up to 1 L.    -   3. Temper to room temperature and readjust volume.    -   4. Measure pH=8.11    -   5. Weigh all ingredients in the percentages in the table below,        including: 4 M Potassium Isobutyrate, propionic acid, acetic        acid, and citric acid to prepare the final FF#2.

-   FF#2 is comprised of potassium isobutyrate, propionic acid, acetic    acid and citric acid.

-   It has a pH of 5.39.

Ingredient % grams K-IBA (4M) 67.0 16.75 Propionic Acid 20.0 5.00 AceticAcid 10.0 2.50 Citric Acid 3.0 0.75 100.0 25.00Lipolyzed Cream product (LC) [Production Lot #140205]:

Specifications LC Target % Moisture 54.61 54-59 % Fat 38.5 34-39 TA(Titratable acidity) 8.5  9-13 pH 4.41 4.2-5.2 Mold Count (cfu/g) <10<10 GC/LC assay (mg/g) Isobutyric Acid 0.07 Propionic Acid 0.00 AceticAcid 0.20

Preparation of Blue Cheese Slurry (BM) (Blue Mold)

-   -   1. Previous plating yielded 3.4 billion CFU/g of Penicillium        roqueforti in the blue cheese.    -   2. Add 1 g Blue Cheese into 9 ml Sodium Citrate (2.0%) buffer        (1/10 dilution).    -   3. Make one dilution (1/10) and 3 serial dilutions of 0.1 ml        into 9.9 ml Sodium Citrate buffer.    -   4. Plate 0.2 ml on each sample and control “C” and “D”.    -   5. BM calculation to equate 6.8 CFU/sample.

Experiment:

-   -   1. Place 100 g of LC as Negative Control “Aa” in white cups and        “Ab” in sterile cups.    -   2. Place 99 g of LC as Negative Control “B” with 1 ml FF#2        (1.0%) in white cup.    -   3. Place 100 g of LC with 0.2 ml BM on the top surface as        Positive Control “C” in white cup.    -   4. Place 100 g of LC with 0.2 ml BM mixed within as Positive        Control “D” in white cup.    -   5. Test white cups “E” will have 1 ml FF#2 (1.0%) in 99 g LC        with 0.2 ml BM inoculated on the top surface.    -   6. Test white cups “F” will have 1 ml FF#2 (1.0%) in 99 g LC        with 0.2 ml BM inoculated within product.    -   7. Number and label white test cups.    -   8. Incubate at 25° C. for 12 weeks (84 days).    -   9. Sample one test cup for initial pH, TA and mold count.    -   10. Test mold counts using PDA (Potato Dextrose Agar        w/1%Tartaric Acid) on weeks 2, 4, 8, and 12.    -   11. Sample final pH and TA at 12 weeks.    -   12. Record Results.    -   13. Obtain a GC/MS assay of Sample A and B to compare FF#2        chemical effects in product.

LC LC LC + LC LC LC 1% FF2 1% FF2 Control 1% FF#2 BM top BM mix BM topBM mix Sample Test “A” “B” “C” “D” “E” “F” Week 1, Day 7 Aa/Ab-1 B1 C1D1 E1 F1 Week 2, Day 14 Aa/Ab-2 B2 C2 D2 E2 F2 Week 4, Day 28 Aa/Ab-3 B3C3 D3 E3 F3 Week 8, Day 56 Aa/Ab-4 B4 C4 D4 E4 F4 Week 12, Day 84Aa/Ab-5 B5 C5 D5 E5 F5

Results

Visible Mold Mold Count Test Cup pH TA (Yes/No) cfu/g Aa1-initial 4.559.73 no <10    Aa1-day 7 no na Aa2-day 14 no Aa3-day 28 yes Aa4-day 56Aa5-day 84 Ab1-initial 4.49 9.8 no <10    Ab1-day 7 no NA Ab2-day 14 yesAb3-day 28 yes Ab4-day 56 Ab5-day 84 B1-initial 4.66 9.79 no <10   B1-day 7 no NA B2-day 14 no B3-day 28 no B4-day 56 B5-day 84 C1-initial4.58 9.53 no 6.8 C1-day 7 no NA C2-day 14 yes C3-day 28 yes C4-day 56C5-day 84 D1-initial 4.64 9.37 no 6.8 D1-day 7 no NA D2-day 14 no D3-day28 no D4-day 56 D5-day 84 E1-initial 4.67 10 no 6.8 E1-day 7 no NAE2-day 14 no E3-day 28 no E4-day 56 E5-day 84 F1-initial 4.72 10.74 no6.8 F1-day 7 no NA F2-day 14 no F3-day 28 no F4-day 56 F5-day 84

As shown by the results of Examples 60a-b, a representative compositionof this invention can be used to effectively inhibit mold growth inotherwise susceptible dairy food products.

Example 61

The composition of Examples 60a-b (FF#2) was tested againstrepresentative strains of fungi and bacteria. The composition was placedin a micro cup in the center of a potato dextrose agar plate with smallplugs of inoculum spaced around the center well micro cup at 2 cm. Thecup contained the amounts of the composition as indicated in Table 16.The plates were incubated for 24 hours at ambient temperature andmeasured. Measurements were made on a control plate and the amount ofinhibition expressed for the composition is presented as the amount ofgrowth versus control plate growth (without composition). The percentinhibition results were calculated after a minimum of two measurementsfor each test organism were completed.

TABLE 16 6 μl in 12.5 μl in 25 μl in Micro cup Micro cup Micro cup TestOrganism % inhibition % inhibition % inhibition Rhizoctonia solani 66 80100 Phytophthora cinnamomi 73 100 100 Verticillum dahliae 40 80 100Sclerotiorum sclerotiorum 19 60 100 Penicillum sp. 15 10 100 Aspergillusfumigatus 80 80 100 Fusarium solani 45 63 100 Pythium ultimum N.D. 100100 Bortytis cinerea N.D. 50 95 E. coli N.D. Trace 100 Bacillus subtilusN.D  Trace Trace

As a further test against the same fungi and bacteria, the compositionwas placed directly as a droplet at the center of a potato dextrose agarplate with small plugs of inoculum spaced around the center at 2 cmincrements. The plates were incubated for 24 hours at ambienttemperature and measured. The amount of composition applied is indicatedin Table 17. Measurements were made on a control plate and test plates.The amount of inhibition expressed for the composition is presented asthe amount of growth versus the control plate growth.

TABLE 17 6 μl on agar 12.5 μl on agar Test Organism % inhibition %inhibition Rhizoctonia solani 100 100 Phytophthora cinnamomi 52 78Verticillum dahliae 0 0 Sclerotiorum sclerotiorum 0 64 Penicillum sp. 033 Aspergillus fumigatus 30 60 Fusarium solani 0 32 Pythium ultimum 100100 Bortytis cinerea 0. 50 E. coli N.D. No growth Bacillus subtilus N.D Trace N.D. = not determined The bacteria controls grew well and the“trace” statement indicates some growth occurred relative to thecontrol.

The results of this example show that the composition is active in thegas phase, as all organisms, at one or all concentrations were affectedduring the course of at least 24 hours. At 25 μl, the effect wasmaximized since most organisms were 100% inhibited (Table 16). When thecomposition was placed directly in the middle of the plate on thesurface, the influence of the composition was somewhat diminished, asthere was undoubtedly diffusion into the agar bed. Nevertheless,antimicrobial activity was observed (Table 17). The higher concentration(12.5 ul) affected both test bacteria and fungi more than the lowerdosage (6 ul) on the agar bed, except for Verticillum.

1. An article comprising a solid carrier component; and a volatile antimicrobial composition incorporated therewith, said antimicrobial composition comprising propanoic acid; and a component selected from a C₂-about C₅ acid ester, an aldehyde and combinations thereof.
 2. The article of claim 1 wherein said antimicrobial composition comprises a said acid ester component, said ester selected from acetic acid esters and isobutyric acid esters and combinations thereof.
 3. The article of claim 2 wherein said acid ester is isobutyl isobutyrate.
 4. The article of claim I wherein said antimicrobial composition comprises a C₂-about C₈ aldehyde component.
 5. The article of claim 4 wherein said aldehyde is benzaldehyde.
 6. The article of claim 1 Wherein said carrier component comprises a clay.
 7. The article of claim 6 wherein said clay comprises a bentonite clay.
 8. The article of claim 7 wherein said antimicrobial composition comprises a rhamnolipid component. 9-45. (canceled)
 46. A composition comprising a propanoic acid component; and a component selected from a C₄-C₆ acid salt component, a C₂.C₅ acid ester component, a C₂-C₈ aldehyde component and combinations thereof.
 47. The composition of claim 46 wherein a said acid salt component is selected from salts of isobutyric acid, salts of citric acid and combinations thereof.
 48. The composition of claim 47 wherein said acid salt component is selected from salts of isobutyric acid and combinations thereof.
 49. The composition of claim 48 wherein said salt is selected from potassium and ammonium salts of isobutyric acid.
 50. The composition of claim 46 wherein said ester component is selected from esters of a C₄ acid and combinations thereof.
 51. The composition of claim 46 wherein said aldehyde component is benzaldehyde.
 52. The composition of claim 46 comprising a C₂-C₆ acid component in addition to said propanoic acid component.
 53. The composition of claim 52 wherein said acid component is selected from acetic acid, isobutyric acid, citric acid and combinations thereof.
 54. The composition of claim 46 comprising propanoic acid and at least one C₄ acid salt.
 55. The composition of claim 54 wherein said acid salt is selected from potassium and ammonium salts of isobutyric acid.
 56. The composition of claim 55 comprising an acid component in addition to said propanoic acid, said additional acid component selected from acetic acid, isobutyric acid, citric acid and combinations thereof.
 57. The composition of claim 46 comprising propanoic acid and at least one C₂-C₅ acid ester component.
 58. The composition of claim 57 comprising at least one C₄ acid ester.
 59. The composition of claim 57 comprising an acid component in addition to said propanoic acid, said additional acid component selected from acetic acid, isobutyric acid, citric acid and combinations thereof.
 60. A composition comprising propanoic acid and at least one C₄-C₆ acid salt component.
 61. The composition of claim 60 wherein said acid salt component is selected from salts of isobutyric acid, salts of citric acid and combinations thereof.
 62. The composition of claim 61 wherein said acid salt component is a salt of isobutyric acid.
 63. The composition of claim 62 wherein said acid salt component is selected from potassium and ammonium salts of isobutyric acid.
 64. The composition of claim 60 comprising an acid component in addition to the said propanoic acid, said additional acid component selected from C₂-C₆acids and combinations thereof.
 65. The composition of claim 64 wherein said additional acid component is selected from acetic acid, isobutyric acid, citric acid and combinations thereof.
 66. The composition of claim 65 selected from a composition consisting essentially of propanoic acid and a salt of isobutyric acid; and a composition consisting essentially of propanoic acid, a salt of isobutyric acid and at least one of acetic acid and citric acid.
 67. An article of manufacture comprising a composition selected from compositions of claim 46, compositions of claim 60 and combinations of said compositions.
 68. The article of claim 67 selected from a human food product, an animal food product, a packaging product and a solid carrier component.
 69. The article of claim 68 wherein said solid carrier comprises a clay.
 70. The article of claim 68 wherein said human food product is selected from processed foods.
 71. The article of claim 70 selected from dairy products. 